PCT

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(54) Title: CYCLIC PEPTIDE ANTIFUNGAL AGENTS

(57) Abstract

Provided are pharmaceutical formulations, and methods of inhibiting fungal and parasitic activity using a compound of formula (I), wherein R', R'', R''', R^{x1}, R^{x2}, R^{y1}, R^{y2}, R^{y3}, R^{y4} and R^0 are as defined hereinabove; and R^2 is (i); R^3 is (ii), (iii), (iv) or (v); R^{3a}, R^{3b}, R^{3c} and R^{3d} are independently hydrogen, C_{1-12} alkyl, C_2-C_{12} alkynyl, C_1-C_{12} alkoxy, C_1-C_{12} alkylthio, halo, or -O-$(CH_2)_m$-[O-$(CH_2)_n]_p$-O-$(C_1$-C_{12} alkyl) or -O-$(CH_2)_q$-X-R^4; m is 2, 3 or 4; n is 2, 3, or 4; p is 0 or 1; q is 2, 3, or 4; X is pyrrolidino, piperidino or piperazino; and R^4 is hydrogen, C_1-C_{12} alkyl, C_3-C_{12} cycloalkyl, benzyl or C_3-C_{12}-cycloalkylmethyl; or a pharmaceutically acceptable salt thereof.

1

CYCLIC PEPTIDE ANTIFUNGAL AGENTS

This invention relates to semi-synthetic cyclic
peptide compounds which are useful as antifungal and
antiparasitic agents and which have improved stability and
water solubility. In particular, it relates to derivatives
of the echinocandin class of cyclic peptides; to methods
for treating fungal and parasitic infections, and to
formulations useful in the methods.

The compounds provided by this invention are
semi-synthetic compounds derived from cyclic peptides which
are produced by culturing various microorganisms. A number
of cyclic peptides are known in the art including
echinocandin B (A30912A), aculeacin, mulundocandin,
sporiofungin, L-671,329, and S31794/F1.

In general, these cyclic peptides may be
structurally characterized as a cyclic hexapeptide core (or
nucleus) with an acylated amino group on one of the core
amino acids. The amino group is typically acylated with a
fatty acid group forming a side chain off the nucleus. For
example, echinocandin B has a linoleoyl side chain while
aculeacin has a palmitoyl side chain.

The fatty acid side chains may be removed from
the cyclic peptide core to provide an amino nucleus (for
example, a compound of formula I, below, where R_2 is
hydrogen). The amino group may then be re-acylated to
provide semi-synthetic compounds such as those claimed in
the present application.

The echinocandin B nucleus has been re-acylated
with certain non-naturally occurring side chain moieties to
provide a number of antifungal agents (see, Debono, U.S.
Pat. No. 4,293,489). Among such antifungal agents is
cilofungin which is represented by a compound of formula I
where R', R", and R''' are methyl; R^{x1}, R^{x2}, R^{y1}, R^{y2}, R^{y3},
R^{y4} and R^0 is hydroxy and R_2 is p-(octyloxy)benzoyl.

2

The present invention provides a compound of the formula:

(I)

wherein:

  R' is hydrogen, methyl or $-CH_2C(O)NH_2$;

  R" and R''' are independently methyl or hydrogen;

  R^{x1} is hydrogen, hydroxy or $-O-R$;

  R is C_1-C_6 alkyl, benzyl, $-(CH_2)_2Si(CH_3)_3$, $-CH_2CHOHCH_2OH$, $-CH_2CH=CH_2$, $-(CH_2)_aCOOH$, $-(CH_2)_bNR^{z1}R^{z2}$, $-(CH_2)_cPOR^{z3}R^{z4}$ or $-[(CH_2)_2O]_d-(C_1-C_6)alkyl$;

  a, b and c are independently 1, 2, 3, 4, 5 or 6;

  R^{z1} and R^{z2} are independently hydrogen, C_1-C_6 alkyl, or R^{z1} and R^{z2} combine to form $-CH_2(CH_2)_eCH_2-$;

  R^{z3} and R^{z4} are independently hydroxy or C_1-C_6 alkoxy;

  d is 1 or 2;

  e is 1, 2 or 3;

  R^{x2}, R^{y1}, R^{y2}, R^{y3} and R^{y4} are independently hydroxy or hydrogen;

  R^0 is hydroxy, $-OP(O)(OH)_2$ or a group of the formulae:

$$-O-\overset{\overset{O}{\|}}{\underset{\underset{OH}{|}}{P}}-R^1 \quad\quad or \quad\quad -O-\overset{\overset{O}{\|}}{\underset{\underset{OH}{|}}{P}}-OR^1 \quad ;$$

R^1 is C_1-C_6 alkyl, phenyl, p-halo-phenyl, p-nitrophenyl, benzyl, p-halo-benzyl or p-nitro-benzyl;

R^2 is $-CH_2$—⬡—R^3 ;

R^3 is

—⬡—R^{3a} ,

$-C{\equiv}C$—⬡—R^{3b} ,

—⬡—$C{\equiv}C$—⬡—R^{3c} , or

—⬡⬡—R^{3d} ;

R^{3a}, R^{3b}, R^{3c} and R^{3d} are independently hydrogen, C_1-C_{12} alkyl, C_2-C_{12} alkynyl, C_1-C_{12} alkoxy, C_1-C_{12} alkylthio, halo, or $-O-(CH_2)_m-[O-(CH_2)_n]_p-O-(C_1-C_{12}$ alkyl) or $-O-(CH_2)_q-X-R^4$;

m is 2, 3 or 4;

n is 2, 3 or 4;

p is 0 or 1;

q is 2, 3 or 4;

X is pyrrolidino, piperidino or piperazino; and

R^4 is hydrogen, C_1-C_{12} alkyl, C_3-C_{12} cycloalkyl, benzyl or C_3-C_{12} cycloalkylmethyl;

or a pharmaceutically acceptable salt thereof.

Also provided are pharmaceutical formulations, methods for inhibiting parasitic or fungal activity and methods of treating fungal or parasitic infections which employ the compounds of the invention.

As used herein, the term "C_1-C_{12} alkyl" refers to a straight or branched alkyl chain having from one to twelve carbon atoms. Typical C_1-C_{12} alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, t-butyl, pentyl, 5-methylpentyl, hexyl, heptyl, 3,3-dimethylheptyl, octyl, 2-methyl-octyl, nonyl, decyl,

4

undecyl, dodecyl and the like. The term "C_1-C_{12} alkyl" includes within its definition the terms "C_1-C_6 alkyl" and C_1-C_4 alkyl."

The term "C_2-C_{12} alkynyl" refers to a straight or branched alkynyl chain having from two to twelve carbon atoms. Typical C_2-C_{12} alkynyl groups include ethynyl, 1-propyn-1-yl, 1-propyn-2-yl, 1-butyn-1-yl, 1-butyn-3-yl, 1-pentyn-3-yl, 4-pentyn-2-yl, 1-hexyn-3-yl, 3-hexyn-1-yl, 5-methyl-3-hexyn-1-yl, 5-octyn-1-yl, 7-octyn-1-yl, 4-decyn-1-yl, 6-decyn-1-yl and the like.

The term "halo" refers to chloro, fluoro, bromo or iodo.

The term "C_1-C_{12} alkylthio" refers to a straight or branched alkyl chain having from one to twelve carbon atoms attached to a sulfur atom. Typical C_1-C_{12} alkylthio groups include methylthio, ethylthio, propylthio, isopropylthio, butylthio, 3-methyl-heptylthio, octylthio, 5,5-dimethyl-hexylthio and the like.

The term "C_1-C_{12} alkoxy" refers to a straight or branched alkyl chain having from one to twelve carbon atoms attached to an oxygen atom. Typical C_1-C_{12} alkoxy groups include methoxy, ethoxy, propoxy, butoxy, sec-butoxy, pentoxy, 5-methyl-hexoxy, heptoxy, octyloxy, decyloxy dodecyloxy and the like. The term "C_1-C_{12} alkyl" includes within its definition the terms "C_1-C_6 alkoxy" and C_1-C_4 alkoxy."

The term "C_3-C_{12} cycloalkyl" refers a saturated hydrocarbon ring structure having from three to twelve carbon atoms. Typical C_3-C_{12} cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl, cyclooctyl and the like.

The term "hydroxy protecting group" refers to a substituent of an hydroxy group that is commonly employed to block or protect the hydroxy functionality while reactions are carried out on other functional groups on the compound. Examples of such hydroxy protecting groups include tetrahydropyranyl, 2-methoxyprop-2-yl, 1-ethoxyeth-

1-yl, methoxymethyl, β-methoxyethoxymethyl,
methylthiomethyl, t-butyl, t-amyl, trityl, 4-methoxytrityl,
4,4'-dimethoxytrityl, 4,4',4"-trimethoxytrityl, benzyl,
allyl, trimethylsilyl, (t-butyl)dimethylsilyl, and 2,2,2-
trichloroethoxycarbonyl and the like. The species of
hydroxy protecting group is not critical so long as the
derivatized hydroxy group is stable to the conditions of
the subsequent reaction(s) and can be removed at the
appropriate point without disrupting the remainder of the
molecule. A preferred hydroxy protecting group is
trimethylsilyl. Further examples of hydroxy protecting
groups are described in T.W. Greene, "Protective Groups in
Organic Synthesis," John Wiley and Sons, New York, N.Y.,
(2nd ed., 1991) chapters 2 and 3. The term "protected
hydroxy" refers to a hydroxy group bonded to one of the
above hydroxy protecting groups.

        The term "amino protecting group" as used in the
specification refers to substituents of the amino group
commonly employed to block or protect the amino
functionality while reacting other functional groups on the
compound. Examples of such amino protecting groups include
formyl, trityl, phthalimido, trichloroacetyl, chloroacetyl,
bromoacetyl, iodoacetyl groups, or urethane-type blocking
groups such as benzyloxycarbonyl, 4-
phenylbenzyloxycarbonyl, 2-methylbenzyloxycarbonyl, 4-
methoxybenzyloxycarbonyl, 4-fluorobenzyloxycarbonyl, 4-
chlorobenzyloxycarbonyl, 3-chlorobenzyloxycarbonyl, 2-
chlorobenzyloxycarbonyl, 2,4-dichlorobenzyloxycarbonyl, 4-
bromobenzyloxycarbonyl, 3-bromobenzyloxycarbonyl, 4-
nitrobenzyloxycarbonyl, 4-cyanobenzyloxycarbonyl, t-
butoxycarbonyl, 2-(4-xenyl)isopropoxycarbonyl, 1,1-
diphenyleth-1-yloxycarbonyl, 1,1-diphenylprop-1-
yloxycarbonyl, 2-phenylprop-2-yloxycarbonyl, 2-(p-toluyl)-
prop-2-yloxycarbonyl, cyclopentanyloxycarbonyl, 1-
methylcyclopentanyloxycarbonyl, cyclohexanyloxycarbonyl, 1-
methylcyclohexanyloxycarbonyl, 2-
methylcyclohexanyloxycarbonyl, 2-(4-toluylsulfonyl)-

6

ethoxycarbonyl, 2-(methylsulfonyl)ethoxycarbonyl, 2-
(triphenylphosphino)-ethoxycarbonyl, fluorenylmethoxy-
carbonyl ("FMOC"), 2-(trimethylsilyl)ethoxycarbonyl,
allyloxycarbonyl, 1-(trimethylsilylmethyl)prop-1-
5   enyloxycarbonyl, 5-benzisoxalylmethoxycarbonyl, 4-
acetoxybenzyloxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-
ethynyl-2-propoxycarbonyl, cyclopropylmethoxycarbonyl, 4-
(decyloxy)benzyloxycarbonyl, isobornyloxycarbonyl, 1-
piperidyloxycarbonyl and the like; benzoylmethylsulfonyl,
10   2-nitrophenylsulfenyl, diphenylphosphine oxide and like
amino protecting groups. The species of amino protecting
group employed is not critical so long as the derivatized
amino group is stable to the condition of subsequent
reaction(s) on other positions of the intermediate molecule
15   and can be selectively removed at the appropriate point
without disrupting the remainder of the molecule including
any other amino protecting group(s). Preferred amino
protecting groups are t-butoxycarbonyl (t-Boc),
allyloxycarbonyl and benzyloxycarbonyl (CbZ). Further
20   examples of groups referred to by the above terms are
described by J. W. Barton, "Protective Groups in Organic
Chemistry", J. G. W. McOmie, Ed., Plenum Press, New York,
N.Y., 1973, Chapter 2, and T. W. Greene, "Protective Groups
in Organic Synthesis", John Wiley and sons, New York, N.Y.,
25   1981, Chapter 7.
          The term "inhibiting", i.e. a method of
inhibiting parasitic or fungal activity, includes stopping,
retarding or prophylactically hindering or preventing the
growth or any attending characteristics and results from
30   the existence of a parasite or fungus.
          The term "contacting", i.e. contacting a
compound of the invention with a parasite or fungus,
includes a union or junction, or apparent touching or
mutual tangency of a compound of the invention with a
35   parasite or fungus. However, the term does not imply any
further limitations to the process, such as by mechanism of
inhibition, and the methods are defined to encompass the

spirit of the invention, which is to inhibit parasitic and
fungal activity by the action of the compounds and their
inherent antiparasitic and antifungal properties, or in
other words, the compounds, used in the claimed methods are
5   the causative agent for such inhibition.
        The term "pharmaceutically acceptable salt" as
used herein, refers to salts of the compounds of the above
formula which are substantially non-toxic to living
organisms. Typical pharmaceutically acceptable salts
10   include those salts prepared by reaction of the compounds
of the present invention with a mineral or organic acid or
an inorganic base. Such salts are known as acid addition
and base addition salts.
        Acids commonly employed to form acid addition
15   salts are mineral acids such as hydrochloric acid,
hydrobromic acid, hydroiodic acid, sulfuric acid,
phosphoric acid and the like, and organic acids such as p-
toluenesulfonic, methanesulfonic acid, oxalic acid, p-
bromophenylsulfonic acid, carbonic acid, succinic acid,
20   citric acid, benzoic acid, acetic acid, and the like.
Examples of such pharmaceutically acceptable salts are the
sulfate, pyrosulfate, bisulfate, sulfite, bisulfite,
phosphate, monohydrogenphosphate, dihydrogenphosphate,
metaphosphate, pyrophosphate, chloride, bromide, iodide,
25   acetate, propionate, decanoate, caprylate, acrylate,
formate, isobutyrate, caproate, heptanoate, propiolate,
oxalate, malonate, succinate, suberate, sebacate, fumarate,
maleate, butyne-1,4-dioate, hexyne-1,6-dioate, benzoate,
chlorobenzoate, methylbenzoate, dinitrobenzoate,
30   hydroxybenzoate, methoxybenzoate, phthalate, sulfonate,
xylenesulfonate, phenylacetate, phenylpropionate,
phenylbutyrate, citrate, lactate, γ-hydroxybutyrate,
glycollate, tartrate, methanesulfonate, propanesulfonate,
naphthalene-1-sulfonate, napththalene-2-sulfonate,
35   mandelate and the like. Preferred pharmaceutically
acceptable acid addition salts are those formed with
mineral acids such as hydrochloric acid and hydrobromic

8

acid, and those formed with organic acids such as maleic
acid and methanesulfonic acid.

Base addition salts include those derived from
inorganic bases, such as ammonium or alkali or alkaline
earth metal hydroxides, carbonates, bicarbonates, and the
like. Such bases useful in preparing the salts of this
invention thus include sodium hydroxide, potassium
hydroxide, ammonium hydroxide, potassium carbonate, sodium
carbonate, sodium bicarbonate, potassium bicarbonate,
calcium hydroxide, calcium carbonate, and the like. The
potassium and sodium salt forms are particularly preferred.

It should be recognized that the particular
counterion forming a part of any salt of this invention is
not of a critical nature, so long as the salt as a whole is
pharmacologically acceptable and as long as the counterion
does not contribute undesired qualities to the salt as a
whole.

Preferred compounds of this invention are those
compounds of formula I where:

R', R" and R''' are each methyl;

R^{y1}, R^{y2}, R^{y3} and R^{y4} are each hydroxy;

R^{x1} is hydrogen, hydroxy or -O-R;

R is methyl, benzyl, $-CH_2CHOHCH_2OH$, $-(CH_2)_bNR^{z1}R^{z2}$
or $-(CH_2)_2POR^{z3}R^{z4}$;

b is 2, 3, 4, 5 or 6;

R^{z1} and R^{z2} are independently hydrogen or C_1-C_4
alkyl;

R^{z3} and R^{z4} are independently hydroxy or methoxy;

R^{x2} is hydrogen or hydroxy;

R^0 is hydroxy, or a group of the formulae:

$$-O-\overset{\overset{O}{\|}}{\underset{\underset{OH}{|}}{P}}-R^1 \quad or \quad -O-\overset{\overset{O}{\|}}{\underset{\underset{OH}{|}}{P}}-OR^1 \quad ;$$

R^1 is methyl;
or a pharmaceutically acceptable salt thereof.

Of these compounds, more preferred are those
compounds of formula I where:

R^{x1} is hydroxy;

R^{x2} is hydroxy;

R^0 is hydroxy;

R^2 is a group of the formula:

 , or

 ;

R^{3c} and R^{3d} are independently hydrogen, C_2-C_{12} alkynyl, C_1-C_{12} alkoxy or $-O-(CH_2)_m-[O-(CH_2)_n]_p-O-(C_1-C_{12}$ alkyl);or a pharmaceutically acceptable salt thereof.

Of these compounds, the most preferred are those compounds where

R^2 is

or

R^2 is

or a pharmaceutically acceptable salt thereof.

The compounds of formula I may be prepared as follows:

10

Reaction Scheme I

(IA)

A. deacylate

(IB)

5

B. N-alkylate

11

I

wherein:

R^{nat} is a naturally occurring cyclic peptide sidechain; and

R', R", R''', R^{x1}, R^{x2}, R^{y1}, R^{y2}, R^{y3}, R^{y4}, R^0 and R^2 are as defined above.

Reaction scheme I, above, is accomplished by carrying out reactions A-C, in order. Once a reaction is complete, the intermediate compound may be isolated by procedures well-known in the art, for example, the compound may be crystallized or precipitated and then collected by filtration, or the reaction solvent may be removed by extraction, evaporation or decantation. The intermediate compound may be further purified, if desired, by common techniques such as crystallization or precipitation, or chromatography over solid supports such as silica gel, alumina and the like, before carrying out the next step of the reaction scheme.

In reaction IA, a naturally occurring cyclic peptide of the formula IA is deacylated using procedures known in the art to provide an amino nucleus of formula IB. This reaction is typically carried out using enzymatic deacylation by exposing the naturally occurring cyclic peptide to a deacylase enzyme. The deacylase enzyme may be obtained from the microorganism *Actinoplanes utahensis* and

used substantially as described in U.S. Patent Nos.
4,293,482 and 4,304,716, herein incorporated by reference.
The deacylase enzyme may also be obtained from the
Pseudomonas species. Deacylation may be accomplished using
5   whole cells of *Actinoplanes utahensis* or *Pseudomonas* or the
crude or purified enzyme thereof or using an immobilized
form of the enzyme. <u>See</u> European Patent Application No. 0
460 882 (December 11, 1991). Examples of naturally
occurring cyclic peptides which may be used as starting
10   materials include aculeacin (palmitoyl side chain),
tetrahydroechinocandin B (stearoyl side chain),
mulundocandin (branched C_{15} side chain), L-671,329
(C_{16} branched side chain), S 31794/F1 (tetradecanoyl side
chain), sporiofungin (C_{15} branched side chain), FR901379
15   (palmitoyl side chain) and the like. A preferred naturally
occurring cyclic peptide is echinocandin B (a compound of
formula IA where R', R" and R''' are each methyl, R^{x1}, R^{x2},
R^{y1}, R^{y2}, R^{y3}, R^{y4} and R^0 are each hydroxy and R^2 is
linoleoyl).

20   In Reaction IB, the resulting amino nucleus is
N-alkylated using reductive amination to provide a compound
of formula I where R^2 is as defined hereinabove. The
reaction is typically carried out by reacting the amino
nucleus of formula IB with an appropriately substituted ·
25   aldehyde of the formula R^2-COH in the presence of a
reducing agent such as sodium cyanoborohydride. The
reaction is typically carried out for one to sixty five
hours at a temperature of from about 20°C to about 100°C in
a mutual inert solvent. Typical solvents for this reaction
30   include dimethylformamide, methanol or a mixture of such
solvents. Solvent choice is not critical so long as the
solvent employed is inert to the ongoing reaction and the
reactants are sufficiently solubilized to effect the
desired reaction. The aldehyde reactant is generally
35   employed in a slight excess relative to the amino nucleus.
        The compounds of formula I where R^{x1} is hydroxy
may be reacted with an appropriately substituted alcohol in

13

the presence of an acid to provide a compound of formula I where R^{x1} is -O-R, where R is C_1-C_6 alkyl, benzyl, -$(CH_2)_2Si(CH_3)_3$, -$CH_2CH=CH_2$, -$(CH_2)_aCOOH$, -$(CH_2)_bNR^{z1}R^{z2}$, -$(CH_2)_cPOR^{z3}R^{z4}$ or -$[(CH_2)_2O]_d$-$(C_1$-$C_6)$alkyl. The reaction is typically carried out in a polar aprotic solvent such as dioxane or dimethylsulfoxide at a temperature of from about 0°C to about 35°C, preferably at about room temperature. Solvent choice is not critical so long as the solvent employed is inert to the ongoing reaction and the reactants are sufficiently solubilized to effect the desired reaction. Preferred acids include p-toluenesulfonic acid, hydrochloric acid and camphorsulfonic acid.

The compounds of formula I where R^{x1} is -$(CH_2)_bNR^{z1}R^{z2}$ where R^{z1} and R^{z2} are hydrogen may be prepared via a protected compound wherein R^{x1} is -$(CH_2)_bNHR^a$ where R^a is an amino protecting group. The resultant protected compound is then deprotected according to procedures known in the art.

The compounds of formula I where R^{x1} is -$CH_2CHOHCH_2OH$ may be prepared by hydroxylating a compound of formula I where R^{x1} is -$CH_2CH=CH_2$ with osmium tetroxide in the presence of a catalyst at a temperature in the range of from about 0°C to about 40°C for about one to twenty four hours in a organic/aqueous solvent mixture, for example dioxane/water. Suitable catalysts include N-methylmorpholine N-oxide (NMO) and the like. Typical solvents suitable for use in this reaction include dimethylformamide, tetrahydrofuran, acetone and dioxane. Solvent choice is not critical so long as the solvent employed is inert to the ongoing reaction and the reactants are sufficiently solubilized to effect the desired reaction. The reaction is preferably conducted at a temperature in the range of from about 20°C to about 30°C for about eighteen to twenty four hours.

The compounds of formula I where R^0 is hydroxy may be phosphorylated by reaction with an appropriately substituted alkyl or phenyl phosphate to provide a compound

14

of formula I where R^0 is $-O-P(O)OH-R^1$ where R^1 is C_1-C_6 alkoxy or phenoxy, or by reaction with an appropriately substituted alkyl or phenyl phosphonic acid to provide a compound of formula I where R^0 is $-O-P(O)OH-R^1$ where R^1 is C_1-C_6 alkyl, or an appropriately substituted phenyl or benzyl moiety, to provide a compound of formula I where R^0 is a group of the formula $-OP(O)OH-R^1$. The phosphonic acid is typically used in an activated form, for example as a phosphonic halide, preferably a phosphonic chloride. The reaction is carried out in the presence of a base such as lithium trimethylsilanolate (LiOTMS), lithium bis(trimethylsilyl)amide (LHMDS), pyridine and the like. The reaction is typically carried out for up to one hour at a temperature from about -30°C to about 0°C in an aprotic solvent such as tetrahydrofuran and dimethylformamide. The reaction is generally complete in about fifteen minutes when carried out under these conditions. The phosphate or phosphonate reactant is generally employed in equimolar proportions to about a one mole excess relative to the amino nucleus in the presence of an equimolar or slight excess of the base. Phosphorylation of an amino nucleus with unprotected aminal hydroxy groups is typically carried out at lower temperatures, for example from about -30°C to about -15°C.

Alternatively, the aminal hydroxy moieties on the compound of formula I are optionally protected with an hydroxy protecting group using procedures known in the art. For example, the reaction is typically carried out by combining the compound of formula I with a suitable hydroxy protecting group in the presence of a catalyst at a temperature in the range of from about 0°C to about 40°C for about one to five hours in a mutual inert solvent. The hydroxy protecting group is generally employed in an amount ranging from about equimolar proportions to about a 100 molar excess relative to the compound of formula I, preferably in a large molar excess. Suitable catalysts include strong acids such as p-toluenesulfonic acid,

camphorsulfonic acid (CSA), hydrochloric acid, sulfuric acid, trifluoroacetic acid and the like. Typical solvents suitable for use in this reaction include any organic solvent such as dioxane. Solvent choice is not critical so long as the solvent employed is inert to the ongoing reaction and the reactants are sufficiently solubilized to effect the desired reaction. The reaction is preferably conducted at a temperature in the range of from about 20°C to about 30°C for about two to four hours. The protected compound of formula I is then phosphorylated as described above. The hydroxy protecting group(s) are then removed according to procedures known in the art to provide a phosphorylated compound of formula I. For example, the protecting groups can be removed by reaction with a Lewis acid in a mutual inert organic solvent such as methylene chloride. Examples of Lewis acids include trimethylsilylbromide, boron trifluoride etherate and the like. The reaction is typically carried out at a temperature of from about 0°C to about 40°C, preferably at a temperature of from about 20°C to about 30°C. A preferred Lewis acid is boron trifluoride etherate.

The dideoxy compounds of formula I are prepared by removing the benzylic and aminal hydroxy groups (R^{x2} and R^{x1}, respectively). The hydroxy groups may be removed by subjecting a non-dideoxy compound of formula I (where R_2 is hydrogen or acyl) to a strong acid and a reducing agent at a temperature of between -5°C and 70°C, in a suitable solvent. Typical strong acids include trichloroacetic acid, trifluoroacetic acid or borontrifluoride etherate. A preferred strong acid is trifluoroacetic acid. Typical reducing agents include sodium cyanoborohydride or triethylsilane. A preferred reducing agent is triethylsilane. Suitable solvents include methylene chloride, chloroform or acetic acid, preferably methylene chloride. The strong acid should be present in an amount of from 2 to 80 mol per mol of substrate, and the reducing agent should be present in an amount of 2 to 80 mol per mol

of substrate. This process affords selective removal of the aminal and benzylic hydroxy groups.

The cyclic peptides used to make the compounds of the present invention may be prepared by fermentation of known microorganisms. For example, the cyclic peptide of formula IB where R', R" and R''' are methyl, R^{x1}, R^{x2}, R^{y1}, R^{y2}, R^{y3}, R^{y4} are hydroxy and R^0 is hydroxy (cyclic nucleus corresponding to A-30912A) may be prepared using the procedure detailed in _Abbott et al._, U.S. Pat. Ser. No. 4,293,482, which is herein incorporated by reference. The cyclic peptide of formula IB where R', R" and R''' are methyl, R^{x1} is hydroxy, R^{x2} is hydrogen, R^{y1}, R^{y2}, R^{y3}, R^{y4} and R^0 is hydroxy (cyclic nucleus corresponding to A-30912B) may be prepared using the procedure detailed in _Abbott et al._, U.S. Pat. Ser. No. 4,299,763, which is herein incorporated by reference. Aculeacin may be prepared using the procedure detailed in _Mizuno et al._, U.S. Pat. Ser. No. 3,978,210 which is herein incorporated by reference. The cyclic peptide of formula IB where R' is $-CH_2C(O)NH_2$, R" is methyl, R''' is hydrogen, R^{x1}, R^{x2}, R^{y1}, R^{y2}, R^{y3}, R^{y4} and R^0 is hydroxy may be prepared by deacylating the cyclic peptide prepared using the procedure detailed in _Chen et al._, U.S. Pat. Ser. No. 5,198,421, which is herein incorporated by reference.

The aldehydes of the formula R^2-COH, used in the reductive aminiation, may be obtained commercially or prepared according to procedures known in the art. For example, an appropriately substituted phenyl boronic acid or biphenyl boronic acid reactant may be reacted with a p-halobenzaldehyde reactant in the presence of a catalyst such as tetrakis(triphenylphosphine)palladium and an inorganic base such as potassium carbonate in a mutual inert organic solvent such as toluene at a temperature of from about 20°C to the reflux temperature of the reaction mixture to provide the corresponding biphenyl aldehydes and terphenyl aldehydes used to prepare the compounds of formula I. The reaction is typically carried out with

equimolar proportions of the boronic acid reactant and the
p-benzaldehyde reactant, or a slight molar excess of the p-
benzaldehyde reactant relative to the boronic acid
reactant, and a 1-2 molar excess of the inorganic base.
The reaction is generally complete after about four to
about ten hours when carried out at reflux temperature in
toluene.

The boronic acid reactant may be prepared by
reacting an appropriately substituted halophenyl or
halobiphenyl reactant with two equivalents of triisopropyl
borate in the presence of an alkyl lithium, for example
sec-butyl lithium, in a mutual inert solvent such as
tetrahydrofuran. The alkyl lithium is typically employed
in a slight molar excess relative to the halophenyl or
halobiphenyl reactant. The alkyl lithium is typically
combined with the solvent by dropwise addition at reduced
temperatures (<-70°C) and allowed to stir for approximately
thirty minutes before the addition of the triisopropyl
borate. The reaction is typically carried out initially at
a temperature of from about -100°C to about -50°C,
preferably from about -75°C to about -85°C for thirty
minutes to two hours and then warmed to room temperature
and reacted for an additional one to three hours. The
reaction is generally complete in from several minutes to
about four hours. When the reaction is substantially
complete, the boronic acid moiety is formed by the addition
of an acid. A preferred acid is a 1N hydrochloric acid
solution.

The R^2-COH aldehydes having an acetylene moiety
may be prepared by reacting an appropriately substituted
acetylene reactant with an appropriately substituted phenyl
or biphenyl reactant of the formula

$$CHO-\langle\ \rangle-\langle\ \rangle-L \quad or \quad CHO-\langle\ \rangle-L$$

where L is a suitable leaving group such as bromo, iodo,
methanesulfonate, toluenesulfonate,
trifluoromethanesulfonate and the like, in the presence of

18

a catalyst and preferably in the presence of an acid
scavenger in a mutual inert solvent such as acetonitrile.
Examples of acid scavengers include triethylamine and
pyridine, preferably triethylamine. A preferred catalyst

5   is formed *in situ* from palladium (II) chloride,
triphenylphosphine and copper (I) iodide. The reaction is
typically carried out for thirty minutes to twenty one
hours at a temperature from about room temperature to the
reflux temperature of reaction mixture. The reaction is

10   generally complete after about two to about six hours when
carried out at reflux temperature.

Alternatively, a suitably substituted phenyl
reactant of the formula $halo-\langle\bigcirc\rangle-L$ may be reacted with an
appropriately substituted acetylene reactant as described

15   above to provide, for example, a compound of the formula
$halo-\langle\bigcirc\rangle-C\equiv C-\langle\bigcirc\rangle-R^{3c}$ which can be coupled with a phenyl
boronic acid reactant as described above.

The following Preparations and Examples further

20   describe how to synthesize the compounds of the present
invention. The terms melting point, proton nuclear
magnetic resonance spectra, mass spectra, infrared spectra,
ultraviolet spectra, elemental analysis, high performance
liquid chromatography, and thin layer chromatography are

25   abbreviated "m.p.", "NMR", "MS", "IR", "UV", "Analysis",
"HPLC", and "TLC", respectively. In addition, the
absorption maxima listed for the IR spectra are only those
of interest and not all of the maxima observed.

30   Preparation 1
                       4-Octyloxybenzaldehyde
A solution containing 3.053 g (25 mmol) of 4-
formylphenol, 6.48 ml (3705 mmol) of 1-bromooctane and 6.9
mg (50 mmol) of potassium carbonate in 100 ml of acetone

35   was refluxed overnight. When the reaction was
substantially complete, as indicated by thin layer

19

chromatagraphy (TLC), the reaction was quenched by the
addition of 100 ml of water. The desired compound was
extracted from the reaction mixture using two 100 ml
portions of diethyl ether. The resultant solution was
5   dried over magnesium sulfate, filtered and then
concentrated *in vacuo* to provide a liquid which was
purified using HPLC (eluent of 10 ethyl acetate in hexane)
to provide the desired compound.
MS(FAB): 235.2 (M+H).

10

Preparation 2

A. [structure] B(OH)$_2$

To a cold (-78C) solution of 10.0 mg (42.9 mmol)
of 1-bromo-4-phenylbenzene, was added 42.9 ml of a 1.3M
15   solution of sec-butyllithium in tetrahydrofuran (55.8
mmol), dropwise. To the resultant mixture was added 14.85
ml (64.35 mmol) of triisopropyl borate, dropwise. The
resultant reaction mixture was stirred for approximately
thirty minutes and then warmed to room temperature and
20   allowed to react for approximately two hours. The reaction
was then quenched by the addition of approximately 50 ml of
1N hydrochloric acid and the resultant mixture was
concentrated *in vacuo* to provide a residue. This residue
was redissolved in diethyl ether, filterd and dried *in*
25   *vacuo* to provide 1.58 g of the desired subtitled compound.

B. H-C(=O)-[structure]

A 2M solution of sodium carbonate was added to a
solution of 2.970 g (15 mmol) of the compound of
30   Preparation 2A in 120 ml of toluene. After degassing the
resultant mixture, 3.470 g (18.75 mmol) of 1-bromo-4-
formylbenzene and 1.713 g (1.5 mmol) of
tetrakis(triphenylphosphine)palladium were added to the
above solution and the resultant reaction mixture was
35   refluxed overnight. When the reaction was substantially

20

complete, as indicated by TLC, the reaction mixture was cooled to room temperature and concentrated *in vacuo* to provide a residue. This residue was redissolved in methylene chloride and washed with two 30 ml portions of

5   brine. The organic portion was then filtered and dried *in vacuo* to provide a solid.

Preparation 3

A.   Br-⟨◯⟩-⟨◯⟩-O(CH₂)₄CH₃

10   A solution containing 50 g (200 mmol) of 4-bromophenol, 33.5 g (298 mmol) of potassium t-butoxide and 40 ml (298 mmol) of 1-iodopentane in 1000 ml of tetrahydrofuran was reacted at reflux temperature for approximately twenty four hours. When the reaction was

15   substantially complete, as indicated by TLC, the reaction was filtered. The resultant filtrate was concentrated *in vacuo* to provide a purple solid. This solid was redissolved in a water/diethyl ether mixture to provide a yellow solution. This solution was washed sequentially

20   with 200 ml of water (twice), 100 ml of 2N sodium hydroxide (twice) and 200 ml of brine (twice), dried over sodium sulfate and then concentrated *in vacuo* to provide a yellow powder. This solid was recrystallized from hot hexanes to provide a white powder.

25   Yield: 45.8 mg (72%).

B.   (OH)₂B-⟨◯⟩-⟨◯⟩-O(CH₂)₄CH₃

           To a cold (-78°C) solution of 10.0 mg (42.9 mmol) of 29 g (90.8 mmol) of the compound of Preparation

30   1A, was added 91 ml of sec-butyllithium in 1000 ml of tetrahydrofuran (118 mmol), dropwise. To the resulting mixture was added 41.9 ml (181.7 mmol) of triisopropyl borate, dropwise. The resultant reaction mixture was stirred for approximately thirty minutes and then warmed to

35   room temperature and allowed to react for approximately two

21

hours. The reaction was then quenched by the addition of
1N hydrochloric acid. The resultant mixture was
concentrated *in vacuo* to provide a residue. This residue
was redissolved in diethyl ether, filtered and dried to
provide the desired subtitled compound.
Yield:

C. $H-\overset{\overset{O}{\|}}{C}$—⟨⟩—⟨⟩—⟨⟩—$O(CH_2)_4CH_3$

A solution of 4.87 mg (26.2 mmol) of 1-bromo-4-
formyl benzene in methanol was added to a solution
containing 6 g (21 mmol) of the compound of Preparation 3B,
60 ml of 2M sodium carbonate and 2.5 g (2.1 mmol) of
tetrakis(triphenylphosphine)palladium in 120 ml of toluene.
The resultant reaction mixture was allowed to react at
reflux temperature for approximately five hours. When the
reaction was substantially complete, as indicated by TLC,
the biphasic mixture was separated and the organic layer
was washed sequentially with water and brine, dried over
magnesium sulfate, filtered and concentrated *in vacuo* to
provide a solid. This solid was recrystallized from hot
hexanes.
MS(FD): 344(M+).

Preparation 4

$H-\overset{\overset{O}{\|}}{C}$—⟨⟩—$C\equiv C$—⟨⟩

To a solution of 2.5 g (13 mmol) of p-bromo
benzaldehyde in 16 ml of acetonitrile, was added 1.5 g
(14 mmol) of phenyl acetylene, 0.55 g (0.52 mmol) of
palladium-on-copper, 0.54 g (2 mmol) of triphenylphosphine,
0.1 g (0.52 mmol) of copper (I) iodide and 32.5 ml of
triethylamine. The resultant reaction mixture was degassed
in vacuo and flushed with argon (three times). After the
reaction mixture was refluxed, under argon, for twenty four
hours, the mixure was cooled to room temperature and

concentrated *in vacuo* to provide a residue. This residue
was purified using flash chromatography (silica gel; eluent
of 20% ethyl acetete in hexanes) to provide 1 g of a white
powder.

Yield: 37%.

^{1}H NMR (CDCl$_3$, 300 MHz):

    δ 7.4 (m, 3H), 7.6 (m, 2H), 7.7, (d, J=7.68 Hz, 2H),
    7.85 (d, J=7.68 Hz, 2H), 10.02 (s, 1H).

<u>Preparation 5</u>

A.   Br—⟨◯⟩—C≡C—⟨◯⟩

To a solution containing 5 g (21.2 mmol) of 1,4-
dibromobenzene, 18.8 mg (0.106 mmol) of palladium (II)
chloride, 55.6 mg (0.212 mmol) of triphenylphosphine and
5.91 ml (0.726 mmol) of triethylamine in 300 ml of
acetonitrile, was added 2.327 g (21.2 mmol) of phenyl
acetylene and 40.0 mg (0.212 mmol) of copper (I) iodide.
The resultant reaction mixture was allowed to react at room
temperature for approximately two days. The crude material
was purified using HPLC (eluent of hexane) to provide 660
mg of a white solid.

                   O
                   ‖
B.   H–C—⟨◯⟩—⟨◯⟩—C≡C—⟨◯⟩

The desired subtitled compound was prepared
substantially in accordance with the procedure detailed in
Preparation 2B, using 3.07 g (11.9 mmol) of the subtitled
compound of Preparation 5A and 1.78 g (11.9 mmol) of 1-
boronic acid-4-formylbenzene, 60 ml of 2<u>M</u> sodium carbonate
and 1.360 g (1.19 mmol) of tetrakis(triphenylphosphine)
palladium in 90 ml of toluene.

MS(FAB): 283.1(M+H).

<u>Example 1</u>

<u>Preparation of the compound of formula I where
R', R" and R''' are each methyl, R^{x1}, R^{x2}, R^{y1}, R^{y2}, R^{y3}, R^{y4}
and R^0 are each hydroxy and R^2 is 4-octyloxybenzyl</u>

A solution containing 1.5 g (1.88 mmol) of the
(A-30912A) nucleus (compound of formula IB where R', R" and
R''' are each methyl, R^{x1}, R^{x2}, R^{y1}, R^{y2}, R^{y3}, R^{y4} and R^0 are
each hydroxy), 697 mg (2.07 mmol) of the compound of
Preparation 1, and 130 mg (2.07 mmol) of sodium
cyanoborohydride in a 1:1 dimethylformamide/methanol
mixture was heated at 70°C overnight. When the reaction
was substantially complete, as indicated by TLC, the
reaction mixture was concentrated *in vacuo* the desired
compound was isolated using HPLC (eluent of 40% aqueous
acetonitrile; 60 ml/min.; 280 nm). The fractions
containing the desired compound were combined and
concentrated *in vacuo* to provide crude material. This
material was purified using HPLC (eluent of 50% aqueous
acetonitrile; 50 ml/min.; 280 nm).
Yield: 19 mg.
MS(FAB) for $C_{49}H_{72}N_7O_{15}$:
         Calcd: 998.5086 (M-H_2O);
         Found: 998.5076.

<u>Example 2</u>

<u>Preparation of the compound of formula I where
R', R" and R''' are each methyl, R^{x1}, R^{x2}, R^{y1}, R^{y2}, R^{y3}, R^{y4}
and R^0 are each hydroxy and</u>

$$R^2 \text{ is } -CH_2-\hexagon\hexagon\hexagon$$

The desired compound was prepared substantially
in accordance with the procedure detailed in Example 1
using 1.5 g (1.88 mmol) of the (A-30912A) nucleus (compound
of formula IB where R', R" and R''' are each methyl, R^{x1},
R^{x2}, R^{y1}, R^{y2}, R^{y3}, R^{y4} and R^0 is hydroxy), 533.5 mg (2.068
mmol) of the compound of Preparation 2B, and 130 mg (2.07
mmol) of sodium cyanoborohydride in 100 ml of a 1:1

24

dimethylformamide/methanol mixture with the exception that
the reaction was substantially complete after approximately
twelve hours. The crude material was purified using HPLC
(eluent of 50% aqueous acetonitrile; 60 ml/min.; 280 nm).
Yield: 24 mg.
MS(FAB) for $C_{53}H_{65}N_7O_{15}$:

        Calcd: 1040.4617 (M+H);
        Found: 1040.4636.

Example 3

Preparation of the compound of formula I where R', R" and R'" are each methyl, R^{x1}, R^{x2}, R^{y1}, R^{y2}, R^{y3}, R^{y4} and R^0 are each hydroxy and

R^2 is $-CH_2$ $O(CH_2)_4CH_3$

The desired compound was prepared substantially
in accordance with the procedure detailed in Example 1
using 1 g (1.25 mmol) of the (A-30912A) nucleus (compound
of formula IB where R', R" and R'" are each methyl, R^{x1},
R^{x2}, R^{y1}, R^{y2}, R^{y3}, R^{y4} and R^0 is hydroxy), 474.0 mg (1.38
mmol) of the compound of Preparation 3C, and 86.7 mg (1.38
mmol) of sodium cyanoborohydride in 100 ml of a 3:1
methanol/dimethylformamide mixture, with the exception that
the reaction was substantially complete after approximately
six hours. After isolating the crude material using HPLC
(eluent of 50% aqueous acetonitrile; 60 ml/min.; 280 nm),
the fractions containing the desired compound were
combined, concentrated *in vacuo* and lyophilized.
MS(FAB): 1132.5 (M+Li).

25

Example 4A

Preparation of the compound of formula I where R', R" and R''' are each methyl, R^{x2}, R^{y1}, R^{y2}, R^{y3}, R^{y4} and R^0 are each hydroxy, R^{x1} is hydrogen, and R² is —CH₂—⟨phenyl⟩—⟨phenyl⟩

A solution of 203.0 mg (0.253 mmol) of the (A-30912A) nucleus (compound of formula IB where R', R" and R''' are each methyl, R^{x1}, R^{x2}, R^{y1}, R^{y2}, R^{y3}, R^{y4} and R^0 is hydroxy) and 83.0 mg (0.455 mmol) of 4-phenylbenzaldehyde in 10 ml of methanol was reacted at reflux temperature.
Yield: 22 mg.
MS(FAB) for $C_{47}H_{61}N_7O_{15}$:

      Calcd: 964.4348 (M+H);
      Found: 964.4304.

Example 4B

Alternate Preparation of the compound of formula I where R', R" and R''' are each methyl, R^{x1}, R^{x2}, R^{y1}, R^{y2}, R^{y3}, R^{y4} and R^0 are each hydroxy and R² is —CH₂—⟨phenyl⟩—⟨phenyl⟩

A solution of 1.5 g (1.88 mmol) of the (A-30912A) nucleus (compound of formula IB where R', R" and R''' are each methyl, R^{x1}, R^{x2}, R^{y1}, R^{y2}, R^{y3}, R^{y4} and R^0 are each hydroxy), 376.8 mg (2.068 mmol) of 4-phenylbenzaldehyde and 130 mg (2.07 mmol) of sodium cyanoborohydride in a 100 ml of a 3:1 methanol/dimethylformamide mixture was allowed to react overnight at reflux temperature. The resultant crude material was isolated using HPLC (eluent of 50% aqueous acetonitrile; 60 ml/min.; 280 nm).
Yield: 68 mg.
MS(FAB) for $C_{47}H_{62}N_7O_{15}$:

      Calcd: 964.4304 (M+H);
      Found: 964.4348.

26

Example 5

Preparation of the compound of formula I where R', R" and R"' are each methyl, R^{x1}, R^{x2}, R^{y1}, R^{y2}, R^{y3}, R^{y4}, and R^0 are each hydroxy and

$$R^2 \text{ is } -CH_2\text{-}\langle\bigcirc\rangle\text{-}C\equiv C\text{-}\langle\bigcirc\rangle$$

The desired compound was prepared substantially in accordance with the procedure detailed in Example 4A, using 375.3 mg (0.495 mmol) of the (A-30912A) nucleus (compound of formula IB where R', R" and R"' are each methyl, R^{x1}, R^{x2}, R^{y1}, R^{y2}, R^{y3}, R^{y4} and R^0 are each hydroxy) and 158.3 mg (0.767 mmol) of the compound of Preparation 4 in 10 ml of ethanol.

Yield: 28 mg.

MS(FAB) for $C_{49}H_{60}N_7O_{14}$:

   Calcd: 970.4198 (M+H-H$_2$O);

   Found: 970.4222.

Example 6

Preparation of the compound of formula I where R', R" and R"' are each methyl, R^{x1}, R^{x2}, R^{y1}, R^{y2}, R^{y3}, R^{y4}, and R^0 are each hydroxy and

$$R^2 \text{ is } -CH_2\text{-}\langle\bigcirc\rangle\text{-}\langle\bigcirc\rangle\text{-}C\equiv C\text{-}\langle\bigcirc\rangle$$

The desired compound was prepared substantially in accordance with the procedure detailed in Example 4A, using 577.8 mg (0.649 mmol) of the (A-30912A) nucleus (compound of formula IB where R', R" and R"' are each methyl, R^{x1}, R^{x2}, R^{y1}, R^{y2}, R^{y3}, R^{y4} and R^0 is hydroxy) and 164.6 mg (0.583 mmol) of the compound of Preparation 5B in 10 ml of ethanol.

Yield: 51 mg.

MS(FAB) for $C_{55}H_{64}N_7O_{14}$:

   Calcd: 1046.4511 (M-H$_2$O);

   Found: 1046.4530.

27

The compounds of formula I exhibit antifungal
and antiparasitic activity. For example, the compounds of
formula I inhibit the growth of various infectious fungi
including *Candida spp.* such as *C. albicans*,

5   *C. parapsilosis*, *C. krusei*, *C. glabrata*, or *C. tropicalis*,
C. lusitaniae; *Torulopus spp.* such as *T. glabrata*;
Aspergillus spp. such as *A. fumigatus*; *Histoplasma spp.*
such as *H. capsulatum*; *Cryptococcus spp.* such as
C. neoformans; *Blastomyces spp.* such as *B. dermatitidis*;

10   *Fusarium spp.*, *Trichophyton spp.*, *Pseudallescheria boydii*,
Coccidioides immitis, *Sporothrix schenckii* and the like.

Antifungal activity of a test compound is
determined *in vitro* by obtaining the minimum inhibitory
concentration (MIC) of the compound using a standard agar

15   dilution test or a disc-diffusion test. The compound is
then tested *in vivo* (in mice) to determine the effective
dose of the test compound for controlling a systemic fungal
infection.

Accordingly, the following compounds were tested

20   for antifungal activity against <u>*C. albicans*</u>.

<u>Table 5</u>
<u>Minimal inhibitory concentration against *C. albicans*</u>

25
<u>Example No.</u>	<u>MIC (μg/ml)</u>
1	0.039
2	0.005
3	5.0
4	0.312
5	20
6	0.039

30

In addition, the effective dose of the following
compounds for controlling a systemic fungal infection

35   (*C. albicans*) was tested *in vivo* (mice).

<u>Table 5</u>

<u>ED$_{50}$ (mouse)</u>

Example No.	ED$_{50}$ (mg/kg)
1	63
2	>20
3	N.T.
4	>2.5
5	>2.5
6	>2.5

N.T. not tested

The compounds of the invention also inhibit the growth of certain organisms primarily responsible for opportunistic infections in immunosuppressed individuals. For example the compounds of the invention inhibit the growth of *Pneumocystis carinii* the causative organism of pneumocystis pneumonia (PCP) in AIDS and other immunocompromised patients. Other protozoans that are inhibited by compounds of formula I include *Plasmodium spp.*, *Leishmania spp.*, *Trypanosoma spp.*, *Cryptosporidium spp.*, *Isospora spp.*, *Cyclospora spp.*, *Trichomonas spp.*, *Microsporidiosis spp.* and the like.

The compounds of formula I are active *in vitro* and *in vivo* and are useful in combating either systemic fungal infections or fungal skin infections. Accordingly, the present invention provides a method of inhibiting fungal activity comprising contacting a compound of formula I, or a pharmaceutically acceptable salt thereof, with a fungus. A preferred method includes inhibiting *Candida albicans* or *Aspergillus fumigatis* activity. The present invention further provides a method of treating a fungal infection which comprises administering an effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof, to a host in need of such treatment. A preferred method includes treating a *Candida albicans* or *Aspergillus fumigatis* infection.

29

With respect to antifungal activity, the term "effective amount," means an amount of a compound of the present invention which is capable of inhibiting fungal activity. The dose administered will vary depending on such factors as the nature and severity of the infection, the age and general health of the host and the tolerance of the host to the antifungal agent. The particular dose regimen likewise may vary according to such factors and may be given in a single daily dose or in multiple doses during the day. The regimen may last from about 2-3 days to about 2-3 weeks or longer. A typical daily dose (administered in single or divided doses) will contain a dosage level of from about 0.01 mg/kg to about 100 mg/kg of body weight of an active compound of this invention. Preferred daily doses generally will be from about 0.1 mg/kg to about 60 mg/kg and ideally from about 2.5 mg/kg to about 40 mg/kg.

The present invention also provides pharmaceutical formulations useful for administering the antifungal compounds of the invention. Accordingly, the present invention also provides a pharmaceutical formulation comprising one or more pharmaceutically acceptable carriers, diluents or excipients and a compound of claim 1. The active ingredient in such formulations comprises from 0.1% to 99.9% by weight of the formulation, more generally from about 10% to about 30% by weight. By "pharmaceutically acceptable" it is meant that the carrier, diluent or excipient is compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

A compound of formula I may be administered parenterally, for example using intramuscular, sub-cutaneous, or intra-peritoneal injection, nasal, or oral means. In addition to these methods of administration, a compound of formula I may be applied topically for skin infections.

For parenteral administration the formulation comprises a compound of formula I and a physiologically

acceptable diluent such as deionized water, physiological saline, 5% dextrose and other commonly used diluents. The formulation may contain a solubilizing agent such as a polyethylene glycol or polypropylene glycol or other known

5   solubilizing agent. Such formulations may be made up in sterile vials containing the antifungal and excipient in a dry powder or lyophilized powder form. Prior to use, a physiologically acceptable diluent is added and the solution withdrawn via syringe for administration to the

10   patient.

The present pharmaceutical formulations are prepared by known procedures using known and readily available ingredients. In making the compositions of the present invention, the active ingredient will generally be

15   admixed with a carrier, or diluted by a carrier, or enclosed within a carrier which may be in the form of a capsule, sachet, paper or other container. When the carrier serves as a diluent, it may be a solid, semi-solid or liquid material which acts as a vehicle, excipient or

20   medium for the active ingredient. Thus, the compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols, (as a solid or in a liquid medium), ointments containing, for example, up to 10% by

25   weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions, sterile packaged powders and the like.

For oral administration, the antifungal compound is filled into gelatin capsules or formed into tablets.

30   Such tablets may also contain a binding agent, a dispersant or other suitable excipients suitable for preparing a proper size tablet for the dosage and particular antifungal compound of the formula I. For pediatric or geriatric use the antifungal compound may be formulated into a flavored

35   liquid suspension, solution or emulsion. A preferred oral formulation is linoleic acid, cremophor RH-60 and water and preferably in the amount (by volume) of 8% linoleic acid,

31

5% cremophor RH-60, 87% sterile water and a compound of
formula I in an amount of from about 2.5 to about 40 mg/ml.

     For topical use the antifungal compound may be
formulated with a dry powder for application to the skin
surface or it may be formulated in a liquid formulation
comprising a solubilizing aqueous liquid or non-aqueous
liquid, e.g., an alcohol or glycol.

     The following formulation examples are
illustrative only and are not intended to limit the scope
of the invention in any way. The term "active ingredient"
means a compound according to formula I or a
pharmaceutically acceptable salt thereof.

Formulation 1

Hard gelatin capsules are prepared using the following
ingredients:

	Quantity (mg/capsule)
Active ingredient	250
Starch, dried	200
Magnesium stearate	10
Total	460 mg

Formulation 2

     A tablet is prepared using the ingredients
below:

	Quantity (mg/capsule)
Active ingredient	250
Cellulose, microcrystalline	400
Silicon dioxide, fumed	10
Stearic acid	5
Total	665 mg

     The components are blended and compressed to
form tablets each weighing 665 mg.

32

Formulation 3

An aerosol solution is prepared containing the
following components:

	Weight
Active ingredient	0.25
Methanol	25.75
Propellant 22 (Chlorodifluoromethane)	74.00
Total	100.00

The active compound is mixed with ethanol and
the mixture added to a portion of the propellant 22, cooled
to
-30°C and transferred to a filling device. The required
amount is then fed to a stainless steel container and
diluted with the remainder of the propellant. The valve
units are then fitted to the container.

Formulation 4

Tablets, each containing 60 mg of active
ingredient, are made as follows:

Active ingredient	60 mg
Starch	45 mg
Microcrystalline cellulose	35 mg
Polyvinylpyrrolidone (as 10% solution in water)	4 mg
Sodium carboxymethyl starch	4.5 mg
Magnesium stearate	0.5 mg
Talc	1 mg
Total	150 mg

The active ingredient, starch and cellulose are
passed through a No. 45 mesh U.S. sieve and mixed
thoroughly. The aqueous solution containing polyvinyl-
pyrrolidone is mixed with the resultant powder, and the
mixture then is passed through a No. 14 mesh U.S. sieve.
The granules so produced are dried at 50°C and passed
through a No. 18 mesh U.S. sieve. The sodium carboxymethyl
starch, magnesium stearate and talc, previously passed

through a No. 60 mesh U.S. sieve, are then added to the granules which, after mixing, are compressed on a tablet machine to yield tablets each weighing 150 mg.

Formulation 5

Capsules, each containing 80 mg of active ingredient, are made as follows:

Active ingredient	80 mg
Starch	59 mg
Microcrystalline cellulose	59 mg
Magnesium stearate	2 mg
Total	200 mg

The active ingredient, cellulose, starch and magnesium stearate are blended, passed through a No. 45 mesh U.S. sieve, and filled into hard gelatin capsules in 200 mg quantities.

Formulation 6

Suppositories, each containing 225 mg of active ingredient, are made as follows:

Active ingredient	225 mg
Saturated fatty acid glycerides	2,000 mg
Total	2,225 mg

The active ingredient is passed through a No. 60 mesh U.S. sieve and suspended in the saturated fatty acid glycerides previously melted using the minimum heat necessary. The mixture is then poured into a suppository mold of nominal 2 g capacity and allowed to cool.

Formulation 7

Suspensions, each containing 50 mg of active ingredient per 5 ml dose, are made as follows:

Active ingredient	50 mg
Sodium carboxymethyl cellulose	50 mg
Syrup	1.25 ml
Benzoic acid solution	0.10 ml
Flavor	q.v.

34

Color	q.v.
Purified water to total	5 ml

The active ingredient is passed through a No. 45 mesh U.S. sieve and mixed with the sodium carboxymethyl cellulose and syrup to form a smooth paste. The benzoic acid solution, flavor and color are diluted with a portion of the water and added, with stirring. Sufficient water is then added to produce the required volume.

Formulation 8

An intravenous formulation may be prepared as follows:

Active ingredient	100 mg
Isotonic saline	1,000 ml

The solution of the above ingredients generally is administered intravenously to a subject at a rate of 1 ml per minute.

The present invention further provides a method for treating or preventing the onset of Pneumocystis pneumonia in a host susceptible to Pneumocystis pneumonia which comprises administering an effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof, to a host in need of such treatment. The compounds of formula I can be used prophylactically to prevent the onset of the infection which is caused by the organism Pneumocystis carinii, or alternatively they can be used to treat a host that has been infected with P. carinii. A compound of formula I may be administered parenterally, for example using intramuscular, intravenous or intra-peritoneal injection, orally or by inhaling directly into the airways of the lungs. A preferred mode of administration is inhalation of an aerosol spray formulation of a compound of formula I.

With respect to antiparasitic activity, the term "effective amount," means an amount of a compound of the present invention which is capable of inhibiting parasitic activity. An effective amount of the compound of formula I

is from about 3 mg/kg of patient body weight to about 100 mg/kg. The amount administered may be in a single daily dose or multiple doses of, for example, two, three or four times daily throughout the treatment regimen. The amount

5   of the individual doses, the route of delivery, the frequency of dosing and the term of therapy will vary according to such factors as the intensity and extent of infection, the age and general health of the patient, the response of the patient to therapy and how well the patient

10   tolerates the drug. It is known that Pneumocystis pneumonia infections in AIDS patients are highly refractory owing to the nature of the infection. For example, in severe, advanced infections the lumenal surface of the air passages becomes clogged with infectious matter and

15   extensive parasite development occurs in lung tissue. A patient with an advanced infection will accordingly require higher doses for longer periods of time. In contrast, immune deficient patients who are not severely infected and who are susceptible to Pneumocystis pneumonia can be

20   treated with lower and less frequent prophylactic doses.

CLAIMS

1.   A compound of the formula:

(I)

wherein:

R' is hydrogen, methyl or $-CH_2C(O)NH_2$;

R" and R''' are independently methyl or hydrogen;

R^{x1} is hydrogen, hydroxy or $-O-R$;

R is C_1-C_6 alkyl, benzyl, $-(CH_2)_2Si(CH_3)_3$, $-CH_2CHOHCH_2OH$, $-CH_2CH=CH_2$, $-(CH_2)_aCOOH$, $-(CH_2)_bNR^{z1}R^{z2}$, $-(CH_2)_cPOR^{z3}R^{z4}$ or $-[(CH_2)_2O]_d-(C_1-C_6)$alkyl;

a, b and c are independently 1, 2, 3, 4, 5 or 6;

R^{z1} and R^{z2} are independently hydrogen, C_1-C_6 alkyl, or R^{z1} and R^{z2} combine to form $-CH_2(CH_2)_eCH_2-$;

R^{z3} and R^{z4} are independently hydroxy or C_1-C_6 alkoxy;

d is 1 or 2;

e is 1, 2 or 3;

R^{x2}, R^{y1}, R^{y2}, R^{y3} and R^{y4} are independently hydroxy or hydrogen;

R^0 is hydroxy, $-OP(O)(OH)_2$ or a group of the formulae:

$$-O-\overset{\overset{O}{\|}}{\underset{\underset{OH}{|}}{P}}-R^1 \quad \text{or} \quad -O-\overset{\overset{O}{\|}}{\underset{\underset{OH}{|}}{P}}-OR^1 \quad ;$$

R^1 is C_1-C_6 alkyl, phenyl, p-halo-phenyl, p-nitrophenyl, benzyl, p-halo-benzyl or p-nitro-benzyl;

R^2 is $-CH_2-\!\!\langle\ \rangle\!\!-R^3$;

R^3 is

$-\!\!\langle\ \rangle\!\!-R^{3a}$,

$-C\equiv C-\!\!\langle\ \rangle\!\!-R^{3b}$,

$-\!\!\langle\ \rangle\!\!-C\equiv C-\!\!\langle\ \rangle\!\!-R^{3c}$, or

$-\!\!\langle\ \rangle\!\!-\!\!\langle\ \rangle\!\!-R^{3d}$;

R^{3a}, R^{3b}, R^{3c} and R^{3d} are independently hydrogen, C_1-C_{12} alkyl, C_2-C_{12} alkynyl, C_1-C_{12} alkoxy, C_1-C_{12} alkylthio, halo, or $-O-(CH_2)_m-[O-(CH_2)_n]_p-O-(C_1$-$C_{12}$ alkyl) or $-O-(CH_2)_q-X-R^4$;

m is 2, 3 or 4;

n is 2, 3 or 4;

p is 0 or 1;

q is 2, 3 or 4;

X is pyrrolidino, piperidino or piperazino; and

R^4 is hydrogen, C_1-C_{12} alkyl, C_3-C_{12} cycloalkyl, benzyl or C_3-C_{12} cycloalkylmethyl;

or a pharmaceutically acceptable salt thereof.

2.   A compound according to claim 1 where:

R', R" and R'" are each methyl;

R^{y1}, R^{y2}, R^{y3} and R^{y4} are each hydroxy;

R^{x1} is hydrogen, hydroxy or $-O-R$;

38

R is methyl, benzyl, $-CH_2CHOHCH_2OH$, $-(CH_2)_bNR^{z1}R^{z2}$ or $-(CH_2)_2POR^{z3}R^{z4}$;

b is 2, 3, 4, 5 or 6;

R^{z1} and R^{z2} are independently hydrogen or C_1-C_4 alkyl;

R^{z3} and R^{z4} are independently hydroxy or methoxy;

R^{x2} is hydrogen or hydroxy;

R^0 is hydroxy or a group of the formulae:

$$-O-\overset{\overset{O}{\|}}{\underset{\underset{OH}{|}}{P}}-R^1 \quad \text{or} \quad -O-\overset{\overset{O}{\|}}{\underset{\underset{OH}{|}}{P}}-OR^1 \quad ;$$

R^1 is methyl;
p-nitrophenyl, benzyl, p-halo-benzyl or p-nitro-benzyl;
or a pharmaceutically acceptable salt thereof.

3. A compound according to claim 2 where:

R^{x1} is hydroxy;

R^{x2} is hydroxy;

R^0 is hydroxy;

R^2 is a group of the formula:

, or

;

R^{3c} and R^{3d} are independently hydrogen, C_2-C_{12} alkynyl, C_1-C_{12} alkoxy or $-O-(CH_2)_m-[O-(CH_2)_n]_p-O-(C_1-C_{12}$ alkyl);
or a pharmaceutically acceptable salt thereof.

4. A compound according to claim 3 where

R^2 is or ;

or a pharmaceutically acceptable salt thereof.

5. A pharmaceutical formulation comprising a compound of formula I, or a pharmaceutically acceptable salt thereof, a claimed in any one of claims 1 to 4,

associated with one or more pharmaceutically acceptable
carriers, diluents or excipients therefor.

5   6.   A compound of formula I, or a pharmaceutically
acceptable salt thereof, a claimed in any one of claims 1
to 4, for use as a pharmaceutical.

7.   A process for preparing a compound of formula I,
or a pharmaceutically acceptable salt thereof, as claimed
10   in any one of claims 1 to 4, comprising alkylating a
compound of formula IB

(IB)

wherein:
15   R', R", R''', R^{x1}, R^{x2}, R^{y1}, R^{y2}, R^{y3}, R^{y4} and R^0 are as
defined in claim 1.

	International application No.
	PCT/US96/07252

A.   CLASSIFICATION OF SUBJECT MATTER

IPC(6)   :CO7K 7/56; A61K 38/12

US CL   :514/9, 11; 530/317

According to International Patent Classification (IPC) or to both national classification and IPC

B.   FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. :   514/9, 11; 530/317

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C.   DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP, A, 0,561,639 (ELI LILLY AND COMPANY) 22 September 1993, page 1 and claim 17.	1-7

☐ Further documents are listed in the continuation of Box C.   ☐ See patent family annex.

*	Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A"	document defining the general state of the art which is not considered to be of particular relevance		
"E"	earlier document published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)		
		"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O"	document referring to an oral disclosure, use, exhibition or other means		
"P"	document published prior to the international filing date but later than the priority date claimed	"&"	document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
05 AUGUST 1996	27 AUG 1996
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231	Authorized officer HOWARD E. SCHAIN
Facsimile No. (703) 305-3230	Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet)(July 1992)*

(51) International Patent Classification 7 :		(11) International Publication Number:	WO 00/11023
C07K 7/50, A61K 38/12	A2	(43) International Publication Date:	2 March 2000 (02.03.00)

(54) Title: RING MODIFIED CYCLIC PEPTIDE ANALOGS

(57) Abstract

A method for modifying the cyclic peptide ring system of Echinocandin–type compounds to produce new analogs having antifungal activity is provided. The inventive process comprises opening the cyclic peptide ring, cleaving the terminal ornithine unit, inserting at least one new amino acid or other synthetic unit and closing the ring to produce a new cyclic peptide ring structure. The process allows one to incorporate features such as water–solubility into the cyclic peptide ring nucleus, sites for further modification, increase or decrease the number of amino acid or peptide units within the ring nucleus, and increase or decrease the total number of members within the ring. The invention further provides novel Echinocandin type compounds and their use as antifungal or anti–parasitic agents.

RING MODIFIED CYCLIC PEPTIDE ANALOGS

CROSS-REFERENCE TO RELATED APPLICATIONS

This is a conversion application of US 60/097,228 filed on August 20,

5   1998.

TECHNICAL FIELD

The present invention relates to the preparation of

ring modified cyclic peptide analogs by replacing peptide unit(s) in the cyclic

10   peptide ring nucleus of natural products or semi-synthetic derivatives thereof, in

particular, Echinocandin-type compounds, and novel semi-synthetic cyclic

peptide compounds produced therefrom.

BACKGROUND ART

15   Echinocandin B is a natural product with antifungal activity that has been

modified in the past in a variety of ways. For example, simple derivatives have

been made including dihydro-and tetrahydro-reduction products and modification

of active groups pendant from the ring nucleus. The most common approach has

been replacement of the N-acyl side chain. For example, U.S. Patent Nos.

20   4,293,489; 4,320,052; 5,166,135; and 5,541,160; and EP 359529; 448353;

447186; 462531; and 561639 describe a variety of N-acyl derivatized

Echinocandin-type compounds that provide varying degrees of antifungal and

antiprotozoal activities.

Other modifications have included acylation of the hydroxyl group of the

25   pendant phenolic group. For example, GB 2,242,194; and EP 448343; 448354;

503960 and 525889 describe the introduction of acyl, phosphono and sulfo

radicals having a charged group at neutral pH to impart water solubility.

1

GB 2,241,956 and EP 448355 describe hydrogen-reduction products of cyclohexapeptide compounds.

A review of the Echinocandin families and their semi-synthetic analogs may be found in Turner, W., et al, *Current Pharmaceutical Design*, **2**, 209-224 (1996).

5 The review compares the *in vitro* and *in vivo* activities of the Echinocandin natural products and their semi-synthetic analogs.

Each of the approaches described above are limited to reactions with active groups pendant to the cyclic peptide ring nucleus. Some have attempted to build the entire cyclic peptide nucleus synthetically. (See, i.e., U.S. Patent No.

10 5,696,084; *J. Am. Chem. Soc.*, **108**, 6041 (1986); Evans, D.A., et al., *J. Am. Chem. Soc.*, **109**, 5151 (1987); *J. Med. Chem.*, 35, 2843 (1992); and Kurokawa, N., et al., *Tetrahedron*, **49**, 6195 (1993).) However, this approach is not cost effective and may lead to racemic mixtures. Therefore, there is a need to provide a more flexible and cost effective process for modifying the cyclic hexapeptide nucleus of

15 natural products to broaden the scope of potential antifungal candidates.

Several investigators have disclosed the preferential cleavage of an amide bond in compounds bearing hydroxyl groups in the delta and gamma positions relative to the amide bond to provide asymmetric lactones using acids such as hydrochloric acid and trifluoroacetic acid; however, none have applied the process

20 to the cleavage of a terminal amino acid group of a linear peptide. (See, i.e., K. Tanaka, et al., *Tetrahedron Lett*, 26(10), 1337 (1985); N. Baba, et al., *Chem Lett* (5), 889 (1989); H. Yoda, et al, *Chem Express*, 4(8), 515 (1989); and Y. Yamamoto, et al., *J Org Chem*, 56(3), 112 (1991).)

BRIEF SUMMARY OF THE INVENTION

The present invention provides a method for modifying the cyclic peptide ring system of Echinocandin-type compounds to produce new analogs having antifungal activity. The inventive process allows one to make changes in the

5   cyclic peptide structure of natural and semi-synthetic products that were previously not possible. For example, one may incorporate features such as water-solubility into the cyclic peptide ring nucleus, sites for further modification, increase or decrease the number of amino acid or peptide units within the ring nucleus, and increase or decrease the total number of members (or atoms) in the

10   ring nucleus.

The process includes the steps of (i) providing a cyclic peptide compound comprising a peptide unit having a γ-hydroxyl group; (ii) opening the ring of the cyclic peptide compound to provide a first linear peptide wherein the peptide unit having a γ-hydroxyl group is the N-terminus peptide unit of the first linear

15   peptide; (iii) cleaving-off the peptide unit having a γ-hydroxyl group to provide a second linear peptide (preferably by adding trifluoroacetic acid or hydrochloric acid to the first linear peptide in an organic solvent); (iv) attaching at least one amino acid, a dipeptide unit or a synthetic unit to the second linear peptide to produce a third linear peptide; (v) cyclizing the third linear peptide to produce a

20   modified cyclic peptide compound having a modified ring nucleus. Alternatively, a second peptide unit may be cleaved-off the second linear peptide produced in step (iii) prior to attaching the amino acid, dipeptide or synthetic unit(s) in step (iv) and subsequent cyclization in step (v). The addition of two or more units in step (iv) may be accomplished in a stepwise fashion (e.g., first one unit is attached

25   then a second unit is attached). Of particular interest is the modification of Echinocandin-type compounds to produce novel cyclic hexapeptide and

3

heptapeptide compounds that show inhibition of fungal and parasitic activity. The

process also provides a convenient means to produce cyclic peptide compounds

having the formulas I and II (including pharmaceutically acceptable salts, esters

and hydrates thereof).

5

I

10   II

wherein

R is an alkyl group, an alkenyl group, an alkynyl group, an aryl group, or

heteroaryl group;

R^2 is -H or -CH_3;

R^3 is -H, -CH_3, -CH_2CONH_2 or -$CH_2CH_2NH_2$;

5   R^4 is -H or -OH;

R^5 is -OH, -OPO_3H_2, or -OSO_3H;

R^6 is -H or -OSO_3H;

R^7 is -CH_3 or -H;

(Y) is represented by the following formula

10

$$-A-\underset{\underset{\displaystyle O}{\|}}{\overset{\overset{\displaystyle NH-W}{|}}{C}}-\underset{\underset{\displaystyle O}{\|}}{C}-NH-\overset{\overset{\displaystyle B}{|}}{CH}-\overset{\overset{\displaystyle O}{\|}}{C}-$$

wherein

A is -$(CH_2)_a$- where a = 1-4, -CHR'-CHR''-$(CH_2)_b$- where R' and R''

are independently -H, -OH, C_6H_5O-, -SH,

15   -NH_2, $C_nH_{n+2}NH$-, $C_nH_{n+2}O$-, $C_nH_{n+2}S$- or -C_nH_{n+2} where

n = 1-4 and b = 0-1, -$(CH_2)_c$-C(O)NH$(CH_2)_d$- where

c = 1-2 and d = 1-2, -N=CH-$(CH_2)_e$- where e = 0-2, -NR'''$(CH_2)_f$-

where R''' is -H, -C(O)CH_2NH_2,

-C(O)CH(NH_2)CH_2NH_2 or -C_nH_{n+2} where n = 1-4 and f = 1-3, -

20          $(CH_2)_g$-SO_2-$(CH_2)_h$- where g = 1-2 and h = 1-2,

$$\underset{\underset{\displaystyle H}{|}}{\overset{\overset{\displaystyle NH}{\|}}{C}}\underset{N}{\diagup}-(CH_2)_i-$$

where i = 1 or 2, or

5

$$\underset{\underset{O}{\|}}{\overset{\overset{CH_2Z}{|}}{\diagup}}\!\!\!\!\!\diagdown NH\!-\!(CH_2)_{\overline{j}}$$

where j is 1 or 2 and Z is an amino group, alkylamino group, or

piperidyl amino group;

5   B is a substituted or unsubstituted C1 to C6 alkyl group (e.g.,

isopropyl, p-hydroxybenzyl, hydroxymethyl, or α-hydroxyethyl);

and W is a hydrogen or C(O)R where R is as defined above.

In another embodiment of the present invention, novel cyclic peptide

compounds are provided having the formulas I and II (above) wherein

10   A is -(CH$_2$)$_a$- where a = 1, 2 or 4, -CHR'-CHR''-(CH$_2$)$_b$- where R' and

R'' are independently -H, -OH, C$_6$H$_5$O-, -SH, -NH$_2$, C$_n$H$_{n+2}$NH-,

C$_n$H$_{n+2}$O-, C$_n$H$_{n+2}$S- or -C$_n$H$_{n+2}$ where n = 1-4 and b = 0, -(CH$_2$)$_c$-

C(O)NH(CH$_2$)$_d$- where c = 1-2 and d = 1-2, -N=CH-(CH$_2$)$_e$- where

e = 0-2, -NR'''(CH$_2$)$_f$- where R''' is -H, -C(O)CH$_2$NH$_2$,

15   -C(O)CH(NH$_2$)CH$_2$NH$_2$ or -C$_n$H$_{n+2}$ where n = 1-4 and

f = 1-3, -(CH$_2$)$_g$-SO$_2$-(CH$_2$)$_h$- where g = 1-2 and

h = 1-2,

$$\underset{\underset{H}{\overset{|}{N}}}{\overset{\overset{NH}{\|}}{\diagup}}\!\!\!\!\!\diagdown (CH_2)_{\overline{i}}$$

20   where i = 1 or 2, or

$$\underset{\underset{O}{\|}}{\overset{\overset{CH_2Z}{|}}{\diagup}}\!\!\!\!\!\diagdown NH\!-\!(CH_2)_{\overline{j}}$$

6

where j is 1 or 2 and Z is an amino group, alkylamino group, or piperidyl amino group.

In yet another embodiment of the present invention, a pharmaceutical composition is provided comprising the novel compounds I and II described above (including pharmaceutically acceptable salts, esters and hydrates thereof) in a pharmaceutically inert carrier. Methods for using the novel compounds and pharmaceutical compositions described above for inhibiting fungal growth and parasitic activity are also provided, as well as a method for treating a fungal infection in a human comprising administering to a human in need of such treatment a therapeutically effective amount of the novel antifungal compound described above.

As used herein, the term "Echinocandin-type compounds" refers to compounds having the following general structure including any simple derivatives thereof:

7

wherein R is an alkyl group, an alkenyl group, an alkynyl group, an aryl group, or

heteroaryl group; R^1 is -H or -OH; R^2 is -H or -CH_3; R^3 is -H, -CH_3, -CH_2CONH_2

or -$CH_2CH_2NH_2$;

R^4 is -H or -OH; R^5 is -OH, -OPO_3H_2, or -OSO_3H; and R^6 is -H or -OSO_3H.

5   The term "alkyl" refers to a hydrocarbon radical of the general formula

C_nH_{2n+1} containing from 1 to 30 carbon atoms unless otherwise indicated. The

alkane radical may be straight, branched, cyclic, or multi-cyclic. The alkane

radical may be substituted or unsubstituted. Similarly, the alkyl portion of an

alkoxy group or alkanoate have the same definition as above.

10   The term "alkenyl" refers to an acyclic hydrocarbon containing at least one

carbon-carbon double bond. The alkene radical may be straight, branched, cyclic,

or multi-cyclic. The alkene radical may be substituted or unsubstituted.

The term "alkynyl" refers to an acyclic hydrocarbon containing at least one

carbon-carbon triple bond. The alkyne radical may be straight, or branched. The

15   alkyne radical may be substituted or unsubstituted.

The term "aryl" refers to aromatic moieties having single (e.g., phenyl) or

fused ring systems (e.g., naphthalene, anthracene, phenanthrene, etc.). The aryl

groups may be substituted or unsubstituted. Substituted aryl groups include a

chain of aromatic moieties (e.g., biphenyl, terphenyl, phenylnaphthalyl, etc.)

20   The term "heteroaryl" refers to aromatic moieties containing at least one

heteratom within the aromatic ring system (e.g., pyrrole, pyridine, indole,

thiophene, furan, benzofuran, imidazole, pyrimidine, purine, benzimidazole,

quinoline, etc.). The aromatic moiety may consist of a single or fused ring

system. The heteroaryl groups may be substituted or unsubstituted.

25   Within the field of organic chemistry and particularly within the field of

organic biochemistry, it is widely understood that significant substitution of

8

compounds is tolerated or even useful. In the present invention, for example, the

term alkyl group allows for substituents which is a classic alkyl, such as methyl,

ethyl, propyl, hexyl, isooctyl, dodecyl, stearyl, etc. The term group specifically

envisions and allows for substitutions on alkyls which are common in the art, such

5   as hydroxy, halogen, alkoxy, carbonyl, keto, ester, carbamato, etc., as well as

including the unsubstituted alkyl moiety. However, it is generally understood by

those skilled in the art that the substituents should be selected so as to not

adversely affect the pharmacological characteristics of the compound or adversely

interfere with the use of the medicament. Suitable substituents for any of the

10   groups defined above include alkyl, alkenyl, alkynyl, aryl, halo, hydroxy, alkoxy,

aryloxy, mercapto, alkylthio, arylthio, mono- and di-alkyl amino, quaternary

ammonium salts, aminoalkoxy, hydroxyalkylamino, aminoalkylthio, carbamyl,

carbonyl, carboxy, glycolyl, glycyl, hydrazino, guanyl, and combinations thereof.

15   DETAILED DESCRIPTION OF THE INVENTION

         The synthetic scheme outlined below illustrates the general procedures for

modifying the cyclic peptide ring system of Echinocandin-type compounds while

maintaining chirality. The cyclic peptide ring of any Echinocandin-type natural

product or semi-synthetic derivative can be opened and the terminal ornithine

20   peptide unit cleaved so long as the γ-hydroxyl group of the ornithine peptide unit

is present and not blocked. The term "natural product" refers to those secondary

metabolites, usually of relatively complex structure, which are of more restricted

distribution and more characteristic of a specific source in nature. Suitable natural

product starting materials belonging to the Echinocandin cyclic peptide family

25   include Echinocandin B, Echinocandin C, Aculeacin Aγ, Mulundocandin,

9

Sporiofungin A, Pneumocandin A_0, WF11899A, and Pneumocandin B_0. For

illustrative purposes, the following synthetic scheme starts with Cilofungin.

Cilofungin (1)

(2)

(3)

(4)

(7)

(4)

(7)

$$\text{CBZ-NH-(X)-}\overset{\overset{\displaystyle HN\text{-}BOC}{|}}{\underset{\displaystyle}{C}}\text{-CO}_2\text{H}$$

$$\text{CBZ-NH-(X)-}\overset{\overset{\displaystyle HN\text{-}BOC}{|}}{\underset{\displaystyle}{C}}\text{-CO}_2\text{H}$$

(5)

(8)

(6)

As shown above, the cyclic hexapeptide ring (1) is first opened using base

catalysis and then reduced with sodium borohydride to give the linear hexapeptide

(2). Upon treatment with triethyl silane in trifluoroacetic acid (TFA), the benzylic

hydroxyl is removed and the ornithine unit is cleaved to give the linear

5   pentapeptide (3). The linear pentapeptide (3) can now be protected and the

primary amide activated to provide an intermediate (4) which can be recyclized

with a new amino acid unit or other synthetic unit to produce a new cyclic

compound (5). Cyclic compound (5) can be further modified by deprotecting and

acylating the pendant amino group (if present) to provide modified cyclic

10   compound (6) having an N-acyl side chain. Those skilled in the art will

appreciate that the N-acyl side chain encompasses a variety of side chain moieties

known in the art. Suitable side chain moieties include substituted and

unsubstituted alkyl groups, alkenyl groups, alkynyl groups, aryl groups, heteroaryl

groups and combinations thereof. Preferably, the side chain contains both a

15   linearly rigid section and a flexible alkyl section to maximize antifungal potency.

In addition, further modifications can be made on any new functionality

introduced by the incorporation of the new amino acid, peptide or synthetic unit(s)

containing such new functionality.

Alternatively, another peptide unit can be cleaved from intermediate (3) to

20   provide a tetrapeptide (7) which can be recyclized with a new amino acid unit,

dipeptide unit, or other synthetic unit to produce a new cyclic compound (8). Like

cyclic compound (5), compound (8) can also be further modified by deprotecting

and acylating the pendant amino group (if present) to attach an N-acyl side chain

or modification of any new functionality introduced through the incorporation of

25   the new amino acid, peptide or synthetic units.

13

As illustrated in the synthetic scheme above, the ring nucleus is selectively opened at the C-terminus L-proline, N-terminus R-ornithine linkage using standard base catalysis well known to those skilled in the art. Once the cyclic hexapeptide is open, then the terminal ornithine amino acid may be cleaved and a

5   new amino acid (or other synthetic unit) attached using standard peptide formation processes (or condensation processes) well known to those skilled in the art. The terminal ornithine unit is cleaved with trifluoroacetic acid or hydrochloric acid in an organic solvent such as methylene chloride, toluene, or dioxane. The preferred reaction condition is trifluoroacetic acid in methylene

10   chloride.

Any amino acid or peptide unit may be attached to the linear peptide. Theoretically, it is also possible to condense other synthetic units onto the peptide that are capable of cyclization. For example, a sulfonamide linkage may be formed between a terminal amino group on the linear peptide and a sulfonyl group

15   on a synthetic unit. Any number of other linkages may also be envisioned; however, the pharmaceutical activity of such compounds are currently unknown.

The insertion of a new amino acid, dipeptide unit or other synthetic unit allows one to change the size of the cyclopeptide ring. The number of atoms in the ring system may be increased or decreased from the original 21 membered

20   Echinocandin ring structure depending upon the particular compound(s) inserted into the ring. Theoretically, the ring size is limited only by the configuration of the linear peptide. If the linear peptide is too short or too long, the ends cannot come into close enough proximity to react and the ends may polymerize with another linear peptide rather than close to form a ring. The optimum

25   configuration of the linear peptide for ring closure will vary depending upon the particular amino acids that make-up the peptide structure. For Echinocandin-type

14

compounds, preferably, the final ring structure contains between 19 to 22

members, more preferably, the final ring structure is a 21- or 22-membered ring,

most preferably the final ring structure is a 21-membered ring.

5   It is well-known that the acyl side chain pendant from the Echinocandin ring

structure plays an important role in the activity of both the natural products and

semi-synthetic Echinocandin type materials. Consequently, any amino acid or

synthetic unit may be used for insertion into the ring so long as the final cyclized

product contains at least one amino group capable of acylation.

When the inserted compound contains more than one unit, the units may be

10   attached one at a time to the linear penta- or tetra-peptide or the individual units

can be combined and then added to the linear penta- or tetra-peptide as a block

unit. Preferably, the units are added as a block unit to minimize racemization.

Acylation of the amino group may be accomplished in a variety of ways well

known to those skilled in the art. For example, the amino group may be acylated

15   by reaction with an appropriately substituted acyl halide, preferably in the

presence of an acid scavenger such as a tertiary amine (e.g., triethylamine). The

reaction is typically carried out at a temperature between about -20°C to 25°C.

Suitable reaction solvents include polar aprotic solvents, such as dioxane or

dimethylformamide. Solvent choice is not critical so long as the solvent

20   employed is inert to the ongoing reaction and the reactants are sufficiently

solubilized to effect the desired reaction.

The amino group may also be acylated by reaction with an appropriately

substituted carboxylic acid, in the presence of a coupling agent. Suitable coupling

agents include dicyclohexylcarbodiimide (DCC), N,N'-carbonyldiimidazole,

25   bis(2-oxo-3-oxazolidinyl)phosphinic chloride (BOP-Cl), N-ethoxycarbonyl-2-

15

ethoxy-1,2-dihydroquinoline (EEDQ), benzotriazole-1-yloxy-

tripyrrolidinophosphonium hexafluorophosphate (PyBOP) and the like.

Alternately, the amino group may be acylated with an activated ester of a

carboxylic acid such as p-nitrophenyl, 2,4,5-trichlorophenyl,

5　　　hydroxybenzotriazole hydrate (HOBT·H$_2$O), pentafluorophenol, and N-

hydroxysuccinimide carboxylate esters. Preferred acylating moieties are the

2,4,5-trichlorophenyl and HOBT carboxylate esters. The reaction is typically ran

1 to 65 hours at a temperature from about 0°C to 30°C in an aprotic solvent. The

reaction is generally complete after about 24 to 48 hours when carried out at a

10　　temperature between about 15°C to 30°C. Suitable solvents include

tetrahydrofuran and dimethylformamide or mixtures thereof. The amino group is

generally present in equimolar proportions relative to the activated ester or with a

slight excess of the amino group.

The compounds of the present invention may be isolated and used per se or in

15　　the form of its pharmaceutically acceptable salt or hydrate. The term

"pharmaceutically acceptable salt" refers to non-toxic acid addition salts derived

from inorganic and organic acids. Suitable salt derivatives include halides,

thiocyanates, sulfates, bisulfates, sulfites, bisulfites, arylsulfonates, alkylsulfates,

phosphonates, monohydrogenphosphates, dihydrogenphosphates,

20 •　　metaphosphates, pyrophosphonates, alkanoates, cycloalkylalkanoates,

arylalkonates, adipates, alginates, aspartates, benzoates, fumarates,

glucoheptanoates, glycerophosphates, lactates, maleates, nicotinates, oxalates,

palmitates, pectinates, picrates, pivalates, succinates, tartarates, citrates,

camphorates, camphorsulfonates, digluconates, trifluoroacetates, and the like.

25　　The ring-modified compounds may be used in a variety of pharmaceutical

formulations. A typical formulation comprises the ring-modified compound (or

16

its pharmaceutically acceptable salt, ester or hydrate) in combination with a

pharmaceutically acceptable carrier, diluent or excipient. The active ingredient is

typically formulated into pharmaceutical dosage forms to provide an easily

controllable dosage of the drug and to give the patient an elegant and easily

5   handleable product. Formulations may comprise from 0.1% to 99.9% by weight

of active ingredient, more generally from about 10% to about 30% by weight.

As used herein, the term "unit dose" or "unit dosage" refers to physically

discrete units that contain a predetermined quantity of active ingredient calculated

to produce a desired therapeutic effect. When a unit dose is administered orally or

10   parenterally, it is typically provided in the form of a tablet, capsule, pill, powder

packet, topical composition, suppository, wafer, measured units in ampoules or in

multidose containers, etc. Alternatively, a unit dose may be administered in the

form of a dry or liquid aerosol which may be inhaled or sprayed.

The dosage to be administered may vary depending upon the physical

15   characteristics of the patient, the severity of the patient's symptoms, and the

means used to administer the drug. The specific dose for a given patient is usually

set by the judgment of the attending physician.

Suitable carriers, diluents and excipients are well known to those skilled in

the art and include materials such as carbohydrates, waxes, water soluble and/or

20   swellable polymers, hydrophilic or hydrophobic materials, gelatin, oils, solvents,

water, and the like. The particular carrier, diluent or excipient used will depend

upon the means and purpose for which the active ingredient is being applied. The

formulations may also include wetting agents, lubricating agents, emulsifiers,

suspending agents, preservatives, sweeteners, stabilizers, perfuming agents,

25   flavoring agents and combinations thereof.

A pharmaceutical composition may be administered using a variety of methods. Suitable methods include topical (e.g., ointments or sprays), oral, injection and inhalation. The particular treatment method used will depend upon the type of infection being addressed.

5   Echinocandin-type compounds have been shown to exhibit antifungal and antiparasitic activity such as growth inhibition of various infectious fungi including Candida spp. (i.e., *C. Albicans, C. Parapsilosis, C. Krusei, C. Glabrata, C. Tropicalis,* or *C. Lusitaniaw*); Torulopus spp.(i.e., *T. Glabrata*); Aspergillus spp. (i.e., *A. Fumigatus*); Histoplasma spp. (i.e., *H. Capsulatum*); Cryptococcus

10   spp. (i.e., *C. Neoformans*); Blastomyces spp. (i.e., *B. Dermatitidis*); Fusarium spp.; Trichophyton spp., *Pseudallescheria boydii, Coccidioides immits, Sporothrix schenckii,* etc.

Compounds of this type also inhibit the growth of certain organisms primarily responsible for opportunistic infections in immunosuppressed individuals, such as

15   growth inhibition of *Pneumocystis carinii* (the causative organism of pneumocystis pneumonia (PCP) in AIDS and other immunocompromised patients. Other protozoans that are inhibited by Echinocandin-type compounds include Plasmodium spp., Leishmania spp., Trypanosoma spp., Cryptosporidium spp., Isospora spp., Cyclospora spp., Trichomnas spp., Microsporidiosis spp., etc.

20   The compounds of the present invention are useful in combating either systemic fungal infections or fungal skin infections. Accordingly, a method is provided for inhibiting fungal activity comprising contacting a compound of formula I or II (or a pharmaceutically acceptable salt, ester or hydrate thereof) with a fungus. A preferred method includes inhibiting *Candida albicans* or

25   *Aspergillus fumigatis* activity. The term "contacting" includes a union or junction, or apparent touching or mutual tangency of a compound of the invention

18

with a parasite or fungus. The term does not imply any further limitations to the process, such as by mechanism of inhibition. The methods are defined to encompass the inhibition of parasitic and fungal activity by the action of the compounds and their inherent antiparasitic and antifungal properties.

5   A method for treating a fungal infection which comprises administering an effective amount of a compound of formula I or II (or a pharmaceutically acceptable salt, ester or hydrate thereof) to a host in need of such treatment is also provided. A preferred method includes treating a *Candida albicans* or *Aspergillus fumigatis* infection. The term "effective amount" refers to an amount of active

10   compound which is capable of inhibiting fungal activity. The dose administered will vary depending on such factors as the nature and severity of the infection, the age and general health of the host and the tolerance of the host to the antifungal agent. The particular dose regimen likewise may vary according to these factors. The medicament may be given in a single daily dose or in multiple doses during

15   the day. The regimen may last from about 2-3 days to about 2-3 weeks or longer. A typical daily dose (administered in single or divided doses) contains a dosage level between about 0.01 mg/kg to 100 mg/kg of body weight of an active compound. Preferred daily doses are generally between about 0.1 mg/kg to 60 mg/kg and more preferably between about 2.5 mg/kg to 40 mg/kg.

20   Although the compounds described herein may be used for inhibiting fungal and parasitic activity in a variety of circumstances (e.g., humans, animals, agriculture, etc.), preferably, the methods of use are limited to the treatment of humans to reduce the potential for developing resistance to the pharmaceutical.

25

EXAMPLES

Unless indicated otherwise, all chemicals can be acquired from commercial suppliers such as Aldrich Chemical (Milwaukee, WI), Sigma, and other commercial sources well-known to those skilled in the art. The following acronyms are representative of the corresponding functional groups or compounds:

BOC = t-butoxycarbonyl, $(CH_3)_3C-O-C(O)-$

CBZ = benzyloxycarbonyl, $C_6H_5CH_2-O-C(O)-$

o-Cl-CBZ = ortho-chlorobenzyloxycarbonyl

FMOC = fluorenylmethyloxycarbonyl

TBDMS = t-butyldimethylsilyl

TFA = trifluoroacetic acid

AcN = acetonitrile

DMF = dimethylformamide

THF = tetrahydrofuran

TDM = 4,4'-tetramethyl-diamino-diphenylmethane

CAM = ceric ammonium molybdate

The following set of examples illustrate the general reaction conditions for cleaving and inserting new unit(s) into a cyclohexapeptide nucleus.

Preparation of Key Intermediates

Ring opening and reduction of cilofungin (1) to give intermediate I-2.

5   **I-2**

To a stirred solution of Cilofungin (1) (100 g; 96 mmol) in 350 ml of 55%

acetonitrile/45% water was added 1 N sodium hydroxide solution (40 ml). The

reaction was monitored by high pressure liquid chromatography (C-18 column,

50% AcN/water, 230 nm). After 1 hour, the reaction mixture contained >90% of

10   the intermediate aldehyde. Next, sodium borohydride (1.8 g; 48 mmol) was

added and the stirring continued for 20 min. HPLC showed complete conversion

to the final alcohol product. The reaction was quenched by adding acetic acid

dropwise until the evolution of gas was complete. Most of the acetonitrile was

removed by rotary evaporation followed by lyophilization to remove the

15   remainder to give 98.1 g of a mixture of the solid product I-2 and inorganic salts.

(93% pure by HPLC)

21

Peptide cleavage and deoxygenation of I-2 to give pentapeptide (I-3)

I-3

The unpurified mixture of Compound I-2 (98.1 g) described above was dissolved in trifluoroacetic acid (300 ml) and dichloromethane (100 ml). The mixture was cooled in an ice bath. Triethylsilane (32 ml; 0.2 mol) was added and the reaction was stirred at 0°C for 1 hour. The ice bath was removed and the reaction was left at ambient temperature for 18 hrs. The solvent was removed *in vacuo* and the residue redissolved in methanol for HPLC purification. The residue was purified by passage through a C-18 column with 50% acetonitrile/water; 0.1% TFA to remove more lipophilic byproducts. The polar peaks were purified with 10% acetonitrile/water; 0.1% TFA. Lyophilization gave 57.8 g (98% yield) of pure pentapeptide trifluoroacetic acid salt (I-3). FAB MS = 653.3 (M+1)

22

Preparation of CBZ pentapeptide (I-4)

I-4

To an ice bath cooled solution of I-3 (50.3 g, 66 mmol) in water (200 ml)
and tetrahydrofuran (100 ml) was added excess solid sodium bicarbonate until no
additional foaming occurred and pH >8. Carbobenzyloxy chloride (10 ml, 70
mmol) was added and the reaction was monitored by HPLC (25% AcN/water,
0.1% TFA, 230 nm). The pH was monitored and occasionally more sodium
bicarbonate was added to keep the solution basic. After 1 hour, the reaction was
complete and the solvent was removed *in vacuo*. The residue was slurried in
methanol, the solid inorganics removed by filtration, and the solution was passed
through a preparative HPLC (25% methanol/water). Removal of solvents gave
25.2 g (49% yield) of I-4 as a white foam. FAB MS = 787.38 (M+1)

23

Preparation of Silyl CBZ pentapeptide (I-5)

I-5

Compound I-4 (25.2 g, 32 mmol), imidazole (20.6 g, 303 mmol), and t-butyldimethylsilyl chloride 45.6 g, 303 mmol) in dimethylformamide (250 ml) were mixed while following the reaction by TLC (25% ethyl acetate/hexane). After 6 hours, the solvent was removed *in vacuo* and the residue was slurried and sonicated in ether. The ether solution was washed with 1N HCl, dried over $MgSO_4$ and reduced *in vacuo* to give a foam. The crude product was purified by flash chromatography (600 g silica, 25% ethyl acetate/hexane) to give 32.9 g (70% yield) of a white foam. NMR data was consistent with the structure I-5.

FAB MS = 1472.9 (M)

Preparation of DiBOC CBZ silyl pentapeptide (I-6)

I-6

Compound I-5 (32.9 g, 22.3 mmol) was dissolved in acetonitrile (250 ml) and tetrahydrofuran (50 ml). Di-t-butyl dicarbonate (16.1 g, 73.6 mmol) and dimethylaminopyridine (299 mg, 2.2 mmol) were added with stirring. The reaction was followed by TLC (20% ethyl acetate/hexane) and an additional 3 g of di-*t*-butyl dicarbonate was added after 2 hrs. After an additional 2.5 hours, several ml of acetic acid were added to quench the dimethylaminopyridine. The solvent was removed *in vacuo* keeping the temperature less than 40⁰C. The residue was chromatographed (500 g silica, 15% ethyl acetate/hexane) to give 33.6 g (89% yield) of a white foam. NMR data was consistent with the structure I-6. FAB MS = 1672.0 (M)

Preparation of the Intermediate linear tetrapeptide (I-7):

I-7

To a solution of Pentapeptide Compound I-3 (5.75 g, 7.50 mmol) in anhydrous DMF (200 ml) was added NaHCO₃ (690 mg, 8.25 mmol) and phenyl isothiocyanate (0.99 ml, 8.25 mmol), and the reaction stirred at room temperature for 36 hours. The solids were removed by filtration and the filtrate was concentrated _in vacuo_. The resulting oil was dissolved in TFA (70 ml) and stirred at room temperature for 1 hour, followed by removal of the solvent in vacuo. The resulting solids were treated with water (150 ml), sonicated, and the insoluble materials were removed by filtration. Reverse phase HPLC of the filtrate (eluting with 4%AcN/0.1% TFA/H₂O) followed by lyophilization gave 3.20 g of a fluffy white solid, 64% yield. The ¹H NMR (300 MHz)spectrum was consistent with the structure I-7. FAB MS (M⁺ of free base)= 552.

Example 1 illustrates the general reaction conditions for converting

pentapeptide intermediate (I-6) into a cyclic hexapeptide analog of an

Echinocandin-type compound.

5

Example 1

Preparation of DiBOC silyl o-Cl-CBZ hexapeptide (E1-1)

E1-1

A solution of N-α-BOC-N-γ-(2-chloro CBZ)-L-ornithine (480 mg, 1.2

10   mmol), N-hydroxysuccinimide (138 mg, 1.2 mmol), and

dicyclohexylcarbodiimide (247 mg, 1.2 mmol) in 4 ml of tetrahydrofuran was

stirred overnight to form the active ester. A solution of I-6 (1.0 g, 0.598 mmol) in

ethanol (5 ml) was added to a slurry of 10% Pd/C (250 mg) in 5 ml of ethanol

followed by 10 ml of glacial acetic acid. The mixture was put under a balloon of

15   H₂ and after 1 hour the starting material was gone. The catalyst was removed by

filtration and the solution was carefully reduced under high vacuum keeping the

temperature under 40⁰C. The resulting oil was dissolved in ether and the

previously prepared tetrahydrofuran solution of active ester was added followed

by excess triethylamine until the solution was basic to pH paper. After stirring for

2 hours, the solution was extracted with saturated NaHCO₃ solution followed by

5   dilute HCl solution and then another portion of saturated NaHCO₃ solution. The

organic layer was dried over MgSO₄ and reduced *in vacuo* to give 0.85 g of the

crude product. Purification by flash chromatography (25% ethyl acetate/hexane)

gave 0.53 g of coupled product E1-1

(47% yield). NMR data was consistent with the structure

10   E1-1. FAB MS = 1922.2 (M+1)

Cyclization of E1-1 to BOC silyl cyclohexapeptide (E1-2)

15   **E1-2**

An ethanol/acetic acid solution (10 ml of each) of E1-1 (0.53 g, 0.27

mmol) with 10% Pd/C (200 mg) was placed under a balloon of hydrogen. After 2

hours, TLC (30% ethyl acetate/hexane) indicated a complete reaction. The

catalyst was removed by filtration and the solvent reduced *in vacuo* at 40⁰C until

the residue was a thick oil. The residue was dissolved in ethyl ether (150 ml) and

excess triethylamine was added until the solution was basic to pH paper (~2 ml).

After 18 hours, TLC indicated a single product spot. The solvent was removed *in*

5   *vacuo* and the residue purified over a flash column to provide 343 mg of a white

solid (81% yield). NMR data was consistent with the structure E1-2.

FAB MS = 1536.0 (M+1)

Removal of protecting groups and coupling of the side chain to give E1-3

10

E1-3

Compound E1-2 (510 mg, 0.332 mmol) was dissolved in 5 ml

trifluoroacetic acid at 0⁰C. After 0.5 hour, water (0.5 ml) was added and the

15   mixture stirred for 0.5 hour longer. The solvent was removed *in vacuo* and the

residue was dissolved in 1N HCl (2 ml) and tetrahydrofuran (2 ml). The solution

was refrigerated for 48 hours after which HPLC analysis (15% AcN/water, 230

nm) showed a single product peak. The solvent was removed under high vacuum

giving a foam residue which was dissolved in dimethylformamide (8 ml). The

terphenyl hydroxybenzotriazole active ester (191 mg, 0.4 mmol) and

triethylamine (0.2 ml, 1.4 mmol) were added to the solution. After 4 hours,

HPLC (60% AcN/water, 230 nm) showed complete conversion to a new product

peak. The solvent was removed under high vacuum and purified by preparative

5   HPLC using the analytical conditions. Solvent removal from the pure fractions

gave 238 mg (66% yield) of a white solid. NMR data was consistent with the

structure E1-3. FAB MS calculated for $C_{58}H_{74}N_7O_{14}$ 1092.5294; found

1092.5301 (M).

The following examples provide further illustrations of converting key

10   intermediate (I-6) into a cyclic hexapeptide analog. In a similar manner I-6 was

converted to each of the following cyclic peptides:

Coupling with Nα-BOC-Nδ-CBZ-D-ornithine and subsequent cyclization

gave 63.9 mg of E1-4 (21-membered ring). FAB MS calculated for $C_{58}H_{74}N_7O_{14}$

1092.5294; found 1092.5280.

15

E1-4

Coupling with Nα-BOC-Nε-CBZ-L-lysine and subsequent cyclization

gave 44.1 mg of E1-5 (22-membered ring). FAB MS calculated for $C_{59}H_{76}N_7O_{14}$

1106.5450; found 1106.5464.

5

E1-5

Coupling with Nα-FMOC-Nδ-CBZ-L-2,4-diaminobutyric acid and

subsequent cyclization gave 65.0 mg of E1-6 (20-membered ring). FAB MS

calculated for $C_{57}H_{72}N_7O_{14} = 1078.5137$; found 1078.5128.

10

E1-6

31

Coupling with Nα-BOC-Nβ-CBZ-L-2,3-diaminopropionic acid and

subsequent cyclization gave 25.5 mg of E1-7 (19-membered ring). FAB MS

calculated for $C_{56}H_{70}N_7O_{14}$ 1064.4981; found 1064.4994.

E1-7

Table 1 summarizes the activity data for compounds E1-3 through E1-7 in

comparison with the following comparative semi-synthetic Echinocandin

compound C1 which has proven *in vitro* and *in vivo* antifungal activity. In a

murine model of organ recovery, Compound C1 significantly reduced the number

of *A. Fumigatus* recovered from the kidneys and was as effective as amphotericin

B on a mg/kg basis when both were administered intraperitoneally. In a

Pneumocystis carinii model, Compound C1 reduced the number of cysts in the

lungs of heavily infected, immunosuppressed rats by more than 99% when

administered orally at 5 mg/kg once daily for 4 days. Prophylactic oral

administration of 1 mg/kg twice daily for 4 weeks resulted in >90% reduction in

all life cycle forms. (see Turner, W.W. and M.J. Rodriguez, *Current*

Pharmaceutical Design, **1996**, 2, p214.)

C1

Antifungal activity of the comparative and test compounds were determined *in vitro* by obtaining the minimum inhibitory concentration (MIC) of the compound

5   using a standard agar dilution test or a disc-diffusion test.

Table 1

Example No.	Minimal Inhibitory Concentration MIC (µg/ml)			
	C. albicans	*C. parapsilosis*	*A. fumigatus*	*Histoplasma capsulatum*
Comparative C1 (21-membered ring)	0.01	0.156	0.02	0.01
E1-3 (21-membered ring)	0.005	0.156	0.078	0.156
E1-4 (21-membered ring)	1.25	>20	20.0	5.0
E1-5 (22-membered ring)	0.02	>20	2.5	0.156
E1-6 (20-membered ring)	0.039	>20	20	0.078
E1-7 (19-membered ring)	0.312	>20	0.625	0.625

Example 2 illustrates the conversion of intermediate I-6 into an azacyclic hexapeptide analog of an Echinocandin-type compound.

10

Example 2

*Preparation of the N-BOC, Benzyl, Aldehyde Derivative of*

L-Homoserine (E2-1)

E2-1

The following procedure described in Baldwin & Flinn, *Tetrahedron Lett.,*
26(31), 3605, (1987) was used to prepare E2-1. A suspension of L-homoserine (5
g, 42 mmol) in 20 ml of water was treated with solid sodium bicarbonate (3.5 g,
42 mmol). The mixture was stirred at room temperature for approx. 10 minutes.
A solution of di-*t*-butyl dicarbonate (BOC anhydride) (13.75 g, 63 mmol) in 20
ml of p-dioxane was added to the mixture and then stirred vigorously at room
temperature for approx. 60 hours. The resulting homogenous solution was
reduced *in vacuo* to yield a colorless oil. A solution of benzyl bromide (10.8 g, 63
mmol) in 50 ml of dimethyl formamide was added to the residue. Another 1.8 g
(0.5 eq more) of solid sodium bicarbonate was added to the reaction and the
mixture was allowed to stir at room temperature overnight. The reaction was
monitored by thin layer chromatography (1:1 chloroform/methanol, plus 1 drop of
glacial acetic acid, developed using TDM stain). The volatiles were removed *in*
vacuo and ethyl acetate was added to the resulting residue. The organic layer was
washed with water (2 times), then brine. The organic layer was dried over sodium
sulfate, filtered and concentrated to yield 14.7 g of a light-yellow oil. The residue
was dissolved in 50 ml of dimethyl sulfoxide. Triethylamine (12.7 g, 126 mmol)
was added and the mixture was cooled in an ice-bath. A suspension of sulfur

34

trioxide/pyridine complex (20 g, 126 mmol) in 50 ml of dimethylsulfoxide was

added with stirring. The ice-bath was removed and the mixture was allowed to

warm to room temperature. After approx. 10 minutes, the reaction mixture was

poured into 200 ml of ice-water. The aqueous layer was extracted twice with

5   ethyl acetate, the ethyl acetate extract was washed once with 0.1N sodium

bisulfate, once with water and then finally with brine. The organic layer was

dried over sodium sulfate, filtered and concentrated *in vacuo* to yield a yellow oil.

Flash silica gel column purification chromatography (approx. 250 g, 30% ethyl

acetate/hexane) yielded 11.1 g (86%) of a light-yellow oil. NMR and elemental

10   analysis (C,H,N) data were consistent with structure E2-1. MS(FD+) = 308

(M+H)

Preparation of the Dimethyl Acetal of Compound E2-1 (E2-2)

15

E2-2

Compound E2-1 (4 g) was dissolved in 50 ml of methanol and then cooled in

an ice-bath. A light blanket of HCl gas was introduced over the stirring solution

(approx. 2-3 seconds of gas allowed in) and the solution was allowed to continue

20   to stir cold. The reaction was monitored by TLC (30% ethyl acetate/hexane,

CAM stain). Additional amounts of HCl gas were added as necessary to drive the

reaction to completion. After approx. 2 hours, the reaction appeared to be

complete. While still cold, the reaction was quenched by adding solid sodium

bicarbonate and keeping the pH slightly on the basic side. The volatiles were

removed *in vacuo*. Ether was added to the residue. The ether layer was washed once with saturated sodium bicarbonate. The aqueous layer was back-extracted with ether. The combined ether extracts were then washed once with brine and dried over sodium sulfate, filtered and concentrated *in vacuo* to yield 4.6 g (100%) of a clear, colorless oil. NMR and elemental analysis (CHN) data were consistent with the structure E2-2.

MS(FD+) = 354 (M+H)

Debenzylation of Compound E2-2 (E2-3)

E2-3

Compound E2-2 (4.2 g, 11.9 mmol) was dissolved in 50 ml of ethyl acetate. The solution was evacuated/purged with nitrogen 3 times, then 1.9 g of 5% palladium on charcoal catalyst was added. The flask was evacuated one more time and then hydrogen was introduced into the flask. The reaction was monitored by TLC (40% ethyl acetate/hexane) and after approx. 2 hours, the reaction was complete. The hydrogen was removed *in vacuo*, the solution was purged with nitrogen, Celite filter aid was added, stirred, filtered through a small bed of Celite on a sintered glass funnel, rinsed with ethyl acetate and the filtrate concentrated *in vacuo* to yield 3.1 g (100%) of a colorless oil. NMR data was consistent with the structure E2-3. MS(FD+) = 264 (M+H) Elemental Analysis (CHN): Theoretical % (C - 50.18; H - 8.04; N - 5.32) Observed % (C - 51.14; H - 7.56; N - 5.65)

Coupling of Compound 2-3 to the Di-BOC-Silyl-CBZ Pentapeptide (I-6) to give (E2-4)

E2-4

Compound I-6 was dissolved in 5 ml of ethanol and added to a slurry of 200 mg of 10% Palladium on charcoal in 10 ml of ethanol (all under an atmosphere of nitrogen). Glacial acetic acid (2 ml) was added and then a hydrogen atmosphere was introduced via a balloon.

Meanwhile, compound E2-3 (0.2 g, 0.76 mmol) was dissolved in 2 ml of tetrahydrofuran (Sure Seal, or freshly distilled from lithium aluminum hydride), 96 mg (0.84 mmol) of N-hydroxysuccinimide was added, followed by 172 mg (0.84 mmol) of dicyclohexylcarbodiimide. The reaction mixture was stirred at room temperature. After approx. 10 minutes, a heavy precipitate was observed. Both reactions were allowed to stir at room temperature approx. 2 to 3 hours and monitored by TLC (25% ethyl acetate/hexane, CAM stain).

After completion of the hydrogenation reaction, the mixture was purged with nitrogen, Celite filter aid was added, stirred, and then filtered through a bed of Celite in a sintered glass funnel. The filtrate was concentrated *in vacuo*, not letting the bath temperature rise above 45°C. The residue was dissolved in 8 ml of

tetrahydrofuran and then approx. 2 ml of triethylamine was added to bring the pH

to between 6 to 7. The newly formed active ester from the second reaction was

filtered directly into this vessel and enough triethylamine was added to keep the

reaction mixture basic (approx. pH 9 - 10). The reaction was stirred at room

5   temperature overnight. The reaction monitored by TLC (25% ethyl

acetate/hexane, CAM stain).

The volatiles were removed *in vacuo*, chloroform was added to the residue,

the organic layer was washed once with 1N hydrochloric acid, once with saturated

sodium bicarbonate solution, once more time with 1N hydrochloric acid, and

10   finally once with brine. The solution was dried over sodium sulfate, filtered, and

concentrated *in vacuo* to yield 1 g of E2-4 as a white foam. The material was

used without further purification in the subsequent reaction. However,

purification can be accomplished using flash silica gel purification

chromatography (approx. 100 g of silica, 20% ethyl acetate/hexane). Yield = 395

15   mg (37%) of a white foam. NMR data was consistent with structure E2-4.

MS(FAB) = 1726 (M - *t*-Butyl)

Preparation of the Acyl Hydrazone of Compound E2-4 (E2-5)

20

<u>E2-5</u>

A flask was charged with compound <u>E2-4</u> (374 mg, 0.21 mmol) and 8 ml of tetrahydrofuran. Hydrazine hydrate (13.6 mg, 0.27 mmol, 13.6 μl) was added and stirred at room temperature. The reaction was monitored by TLC (25% ethyl

5   acetate/hexane, CAM stain). After approx. 15 minutes, the volatiles were removed to yield a white foam. Flash silica gel column chromatography (approx. 25 g, 25% → 50% ethyl acetate/hexane) yielded 250 mg (75%) of a white foam. NMR data was consistent with the structure <u>E2-5</u>. MS(FAB) = 1541(M - *t*-Butyl)

10   *Cyclization of Compound E2-5 (E2-6)*

<u>E2-6</u>

Stannous chloride (1.5 g) and solid sodium bicarbonate (400 mg) was

15   suspended in 800 ml of methylene chloride. The mixture was stirred for approx. 15 minutes at room temperature. A solution of compound <u>E2-5</u> (3.2 g) was added in 100 ml of methylene chloride. The container containing compound <u>E2-5</u> was rinsed with another 100 ml of solvent and added to the reaction vessel. The

reaction was monitored by TLC (40% ethyl acetate/hexane, CAM stain). After

approx. 3 hours, the residual solids were filtered off and the filtrate concentrated

in vacuo to yield 3 g (100%) of E2-6 as a pale-yellow solid. Any attempt at

purification failed due to instability. MS(FAB) = 1534 (parent ion)

5

*Borohydride Reduction of Compound E2-6 (E2-7)*

E2-7

10   Compound E2-6 (6 g, 3.9 mmol) was dissolved in 400 ml of tetrahydrofuran,

425 mg (6.76 mmol) of sodium cyanoborohydride was added followed by 1 ml of

glacial acetic acid. The mixture was allowed to stir at room temperature while

monitoring by TLC (40% ethyl acetate/hexane, CAM stain). After approx. 2

hours, the volatiles were removed *in vacuo*, ethyl acetate was added to the residue,

15   washed twice with water, once with brine, dried over sodium sulfate, filtered, and

concentrated *in vacuo* to yield 5.2 g of a white foam. The solid was dissolved in

125 ml of methanol and allowed to stir at room temperature for 6 days. The

volatiles were removed *in vacuo* to yield 4.8 g of a white foam. Flash silica gel

column chromatography (approx. 200 g, 25% → 35% ethyl acetate/hexane)

yielded 2.2 g (37%) of a white foam. NMR data was consistent with the structure

E2-7. MS(FAB+) = 1537 (M+H)

5   *CBz Protection of Compound E2-7 (E2-8)*

E2-8

A solution of Compound E2-7 (650 mg, 0.4 mmol) in 15 ml of

10   tetrahydrofuran and solid sodium bicarbonate (67 mg) were added to a reaction

vessel fitted with rubber septum and stir bar. The solution was flushed with

nitrogen and stirred. The mixture was cooled in an ice-bath and benzyl

chloroformate (144 mg, 0.8 mmol, 12 μl) was added via syringe. The mixture

was stirred cold for approx. 1 hour. The ice-bath was removed and the mixture

15   was allowed to stir at room temperature for approx. 3 hrs. The reaction was

monitored by TLC (20% and 40% ethyl acetate/hexane, CAM stain). The

volatiles were removed *in vacuo*. The residue was dissolved in ether, washed

twice with water, once with dilute hydrochloric acid quickly, once with saturated

sodium bicarbonate solution, once with brine, dried over sodium sulfate, filtered,

and concentrated *in vacuo* to yield 700 mg of a white foam. Flash silica gel

column chromatography (35 g of silica, 20% ethyl acetate/hexane) yielded 460

mg (65%) of a white foam. NMR data was consistent with the structure

5   E2-8. MS(FAB) = 1670 (parent ion)

Deprotection of Compound E2-8 (E2-9)

E2-9

Compound E2-8 (1.2 g, 0.72 mmol) was dissolved in cold trifluoroacetic

acid (10 ml), placed in an ice-bath and stirred for approx. 1.5 hrs. Cold water (5

ml) was added and stirring continued in the ice-bath for approx. 1 hr. The

volatiles were removed *in vacuo*, 5 ml of tetrahydrofuran and 5 ml of 1N

15   hydrochloric acid was added and stirred overnight at room temperature.

The volatiles were removed *in vacuo*, toluene was added to the residue and

then evaporated. The procedure was repeated two more times in order to remove

the excess trifluoroacetic acid. Ether was added to the residue and then sonicated

to yield a white solid. The ether was filtered off and the residue rinsed several

times with ether. The residue was dried under high vacuum to yield 660 mg

(100%) of a white solid. Analysis by RP-HPLC (C-18 Bondapak, 70:20:10

AcN/water/1% TFA, 230 nm) shows material to be 97% pure. NMR data was

consistent with the structure E2-9. MS(FAB) = 885.5 (M+H)

5

*Preparation of compound(E2-10(b))*

E2-10(b)

10   Compound E2-9 (600 mg, 0.68 mmol) was dissolved in 10 ml of

dimethylformamide and enough diisopropyl ethylamine added to make the

solution basic to pH paper (approx. 0.5 ml). The hydroxybenzotriazole active

ester of the terphenyl side chain (388 mg, 0.81 mmol) was added to the reaction

vessel and allowed to stir at room temperature overnight. The reaction was

15   monitored by RP-HPLC (60:40 AcN/water, 230 nm).

The solvent was removed *in vacuo*, and a 1:1 mixture of methanol/acetonitrile

was added to the resulting residue, followed by stirring and then filtration. The

resulting white solid was suspended in ether, stirred, filtered, and the process

repeated. The same procedure was performed using methylene chloride, then

20   finally one time more with ether. The residue was dried under vacuum to yield

735 mg (88%) of a white solid - Compound E2-10(a). MS(FAB)= 1227.6 (parent ion)

The white solid (632 mg, 0.5 mmol) was suspended in glacial acetic acid (100 ml) and subjected to catalytic hydrogenation under a balloon of hydrogen, overnight (100 mg of 10% palladium on charcoal). The reaction was monitored by reverse-phase HPLC (C-18 Bondapak, 60:30:10 AcN/water/1% TFA, 230 nm). The reaction vessel was purged with nitrogen, Celite filter aid was added, stirred, filtered through a bed of Celite in a sintered glass funnel, the catalyst was washed with a 1:1:1 mixture of methanol/AcN/water, and the filtrate was concentrated to dryness. Toluene was added and then allowed to evaporate to dryness yielding 440 mg (81%) of a white solid - Compound E2-10(b). MS(FAB) = 1093.5 (parent ion)

Alkylation of deprotected acyl hydrazide nucleus E2-10(b), where R is methyl, ethyl or n-propyl (E2-11)

E2-11

The following procedure illustrates a typical preparation for the alkylations.

Compound E2-10(b) (100 mg, 0.086 mmol) was dissolved or suspended in 10 ml

of dimethyl formamide. Two equivalents of the corresponding aldehyde (for

formaldehyde use 5.2 mg (15 μl)) was added (for acetaldehyde use 7.6 mg (10 μl)

and for propionaldehyde use 10 mg (12.5 μl), all are 0.173 mmol), followed by

enough glacial acetic acid (approx. 3 - 4 drops) to make the mixture acidic.

5   Sodium cyanoborohydride (11 mg, 0.173 mmol) was added and the mixture

stirred at room temperature, overnight. The reaction was monitored by reverse-

phase HPLC (C-18 Bondapak, AcN/water/1% TFA (55:35:10), 280 nm). The

reaction was quenched with water to obtain a clear solution and a white gummy

material in the bottom of the flask. The solvents were removed *in vacuo*,

10   acetonitrile was added, filtered, and washed with ether to obtain a white powder

(150 mg for methyl, 250 mg for ethyl, and 250 mg for propyl). All alkylated

materials were isolated using preparative RP-HPLC(50:40:10 AcN/water/1% HCl,

230 nm for methyl and ethyl and 55:35:10 AcN/water/1% HCl, 230 nm for

propyl).

15   Yield : 64 mg for the methyl derivative E2-11(a) having a MS(FAB) = 1107.54

(exact mass)

     59 mg for the ethyl derivative E2-11(b) having MS(FAB) = 1121.55 (exact

mass)

     73 mg for the propyl derivative E2-11(c) having a MS(FAB) = 1135.57 (exact

20   mass)

Preparation of the product from coupling glycine to compound E2-7 (E2-12)

<u>E2-12</u>

5   CBz-Glycine (2 g, 9.6 mmol) was dissolved in 25 ml of tetrahydrofuran,

pentafluorophenol (2.2 g, 11.9 mmol)was added, followed by 1-[3-

(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (EDAC) (2.2 g, 11.5

mmol). The mixture was stirred at room temperature under nitrogen. The

reaction was monitored by TLC (40% ethyl acetate/hexane, UV and CAM stain).

10   After approx. 1 hour, the solvent was removed *in vacuo*, the residue dissolved in

methylene chloride, the organic layer washed once with 1M sodium bisulfate

solution, thrice with 1N sodium hydroxide and finally once with brine. The

organic layer was dried over sodium sulfate, filtered and concentrated *in vacuo* to

yield 3.3 g (92%) of a light-pink solid. The material had consistent NMR data.

15   Compound <u>E2-7</u> (700 mg, 0.45 mmol) was dissolved in 15 ml of

tetrahydrofuran. The active ester from above (504 mg, 1.3 mmol) was added, plus

a few drops of triethylamine. The mixture was heated near reflux for approx. 4

hours, then cooled to room temperature and allowed to stir overnight. The

volatiles were removed *in vacuo*, ether was added to the residue, washed twice

20   with 1N sodium hydroxide, once with brine, dried over sodium sulfate, filtered,

and concentrated *in vacuo* to yield 1.1 g of a white foam. Flash silica gel column

cleanup (20 ⊠   30% ethyl acetate/hexane) yielded 0.75 g (95%) of a white foam.

The material had satisfactory NMR data. MS(FAB) : 1727.9 (parent ion)

   The silyl and BOC protecting groups were removed following the previous

5   procedure for preparation of compound E2-9. The reaction was monitored by RP-

HPLC (25:65:10 AcN/water/1% TFA, 230 nm). Yield = 490 mg of a white

powder

   The terphenyl side chain was coupled to the above product according to the

method for preparation of compound E2-10(b). Reacting amounts: 490 mg of the

10   above compound, 260 mg (0.544 mmol) of the terphenyl active ester, 10 ml of

dimethyl formamide, and enough diisopropylethylamine to make the reaction

basic. The reaction was followed by RP-HPLC (25:65:10 AcN/water/1% TFA for

starting material, 230 nm and 60:30:10 AcN/water/1% TFA for product, 280 nm).

The solvent was removed under high vacuum to yield a white, gummy residue.

15   Trituration from ether (2 washes) yielded 800 mg of a pale-yellow powder.

   The above product was subjected to the same hydrogenolysis conditions as

that for compound E2-10(a). Reagent amounts: 400 mg of 10% palladium on

charcoal, 100 ml of glacial acetic acid. Overnight reaction yielded 600 mg of an

off-white solid. The product was isolated using RP-HPLC (AcN/water/1% TFA

20   (50:40:10), 280 nm).

Yield = 188 mg of a white powder. NMR data was consistent with structure E2-

12. MS(FAB) = 1150.54 (exact mass)

25

Preparation of the product from coupling diaminopropionic acid to compound
E2-7 (E2-13)

E2-13

5

Following the above procedure for the preparation of compound E2-12, the active

ester of L-di-CBz-diamino-propionic acid was prepared. Reacting stoichiometries

were: L-di-CBz-diaminopropionic acid - 581 mg (1.56 mmol), pentafluorophenol

- 344 mg (1.87 mmol), 1-[3-(dimethylamino) propyl]-3-ethylcarbodiimide

10   hydrochloride (EDAC) - 360 mg (1.87 mmol), tetrahydrofuran - 12 ml. TLC

system : chloroform/methanol/glacial acetic acid, 75:25:drop, for starting

material; 40% ethyl acetate/hexane, TDM stain for product. Same workup

yielded 720 mg (86%) of a white solid. The material had satisfactory NMR data.

Again, following the above procedure for coupling the active ester (710 mg,

15   1.32 mmol) to compound E2-7 (800 mg, 0.52 mmol) and refluxing for 2 days,

standard workup yielded 1.1 g of a white foam. Flash silica gel column

chromatography (100 g of silica, 20% ethyl acetate/hexane) yielded 0.56 g (57%

yield) of a white foam. MS(FAB) = 1891 (parent ion)

The silyl and BOC protecting groups were removed following the previous

procedure for preparation of compound E2-9. The reaction was monitored by RP-

HPLC (50:40:10 AcN/water/1% TFA, 230 nm). Yield = 550 mg

The terphenyl side chain was coupled to the above product according to the

5   method for preparation of compound E2-10(b). Reacting amounts: 550 mg of the

above compound, 239 mg (0.5 mmol) of the terphenyl active ester, 10 ml of

dimethylformamide, and enough diisopropylethylamine to make the reaction

basic. The reaction was followed by RP-HPLC (70:20:10 AcN/water/1% TFA for

starting material, 230 nm and 40:50:10 AcN/water/1% TFA for product, 280 nm).

10   The solvent was removed under high vacuum to yield a white, gummy residue.

Trituration from ether (2 washes) yielded 850 mg of an off-white powder.

The above product was subjected to the same hydrogenolysis conditions as

that for compound E2-10(a). Reagent amounts: 400 mg of 10% palladium on

charcoal, 100 ml of glacial acetic acid. Overnight reaction yielded 580 mg of an

15   off-white solid. The product was isolated using RP-HPLC (gradient

AcN/water/1% TFA (45/45/10 → 55/10 elution scheme, 280 nm). Two separate

products were isolated, both having the same molecular weight. It was never

determined what the relative stereochemistries of the two compounds were. The

yield of one E2-13 isomer was 76 mg and the

20   yield of the other E2-13 isomer was 116 mg.

MS(FAB) = 1179.6 (parent ion) for both

Table 2 summarizes the activity data for compounds E2-9 through E2-13

in comparison with the comparative semi-synthetic Echinocandin compound C1.

The same testing procedures were used as described in Example 1 above.

49

Table 2

Example No.	Minimal Inhibitory Concentration (MIC) µg/ml			
	C. albicans	C. parapsilosis	A. fumigatus	Histoplasma capsulatum
Comparative C1	0.01	0.156	0.02	0.01
E2-10(a)	0.625	>20	0.625	5.0
E2-10(b)	0.01	0.156	0.156	0.156
E2-11(a) R=methyl TFA salt	0.005	0.156	0.039	0.78
E2-11(a) R=methyl HCl salt	0.001	0.156	0.078	0.02
E2-11(b) R=ethyl HCl salt	0.001	0.156	0.312	0.02
E2-11(c) R=n-propyl HCl salt	0.312	1.25	0.156	0.312
E2-12	0.01	0.312	0.156	0.039
E2-13 (isomer 1)	0.078	2.5	0.625	1.25
E2-13 (isomer 2)	0.156	20	1.25	10

Example 3 further illustrates the insertion of a new unit to yield an analog

of an Echinocandin-type compound.

Example 3

CbzNHCH$_2$CH$_2$SH was prepared as described in I. Shinkai, T. Liu, R.

Reamer, M. Sletzinger, *Synthesis*, 924, 1980.

N-BOC-O-toluenesulfonyl serine methyl ester was prepared as described

in N. A. Sasaki, C. Hashimoto, P. A. Potier, *Tetrahedron Lett.*, 28, 6069-6072,

1987.

Preparation o(R)-2-[(tert-Butoxy-carbonyl)amino]-3-[(2'-N-benzyloxycarbonyl

amino)ethanethio]methyl propiolate (E3-1)

E3-1

5

Sodium hydride (72 mg, 1.8 mmol, 60% suspension in mineral oil) was

trituated with hexanes under a nitrogen atmosphere in a 3-necked round

bottomed flask. The flask was placed in a 0°C bath and a solution of CbzNHCH-

$_2$CH$_2$SH (470 mg, 1.87 mmol, 85% pure) in DMF (5 ml) was added. The resulting

10   mixture was stirred at 0°C for 20 min which resulted in a colorless solution. N-

BOC-O-toluenesulfonyl serine methyl ester

(671 mg, 1.8 mmol) was added as a solid and washed into the flask with an

additional 2 ml of DMF. The resulting mixture was stirred at 0°C for 3 hours then

poured into water and extracted twice with ethyl acetate. The combined organic

15   extracts were washed with water, 1N sodium hydroxide solution, water, and brine,

then dried over MgSO$_4$ and concentrated *in vacuo* to give 900 mg of an oil. Radial

chromatography eluting with 25% -> 50% ethyl acetate in hexanes gave 570 mg

76% of the desired (R)-2-[(tert-Butoxy-carbonyl)amino]-3-[(2'-N-

benzyloxycarbonyl amino)ethanethio]methyl propiolate.

20   Anal. calculated for C$_{19}$H$_{28}$N$_2$O$_6$S, C: 55.32, H: 6.84, N: 6.79; Found C: 55.26, H:

6.95, N: 6.94. [α]$_D$ -1.9° (c=10).

51

Preparation of (R)-2-[(tert-Butoxycarbonyl)amino]-3-[(2'-N-benzyloxycarbonyl amino)ethanethio]propiolic acid. (E3-2)

E3-2

Compound E3-1 (520 mg, 1.26 mmol)in dioxane (3 ml) was treated with 0.5M LiOH solution (3 ml) and stirred at room temperature overnight. The dioxane was removed *in vacuo* and the residue partitioned between 1N hydrochloric acid solution and ethyl acetate. The organic extract was washed with brine, dried over MgSO$_4$ and concentrated *in vacuo* to give 500 mg of a colorless oil corresponding to compound E3-2. Anal. calculated for C$_{18}$H$_{26}$N$_2$O$_6$S+0.4H$_2$O, C: 53.29, H: 6.65, N: 6.90; Found C: 53.61, H: 6.82, N: 6.85. [α]$_D$ -0.9° (c=10). MS: (m+1) 399.

Preparation of (R)-2-[(tert-Butoxycarbonyl)amino]-3-[(2'-N-benzyloxycarbonyl
amino)ethanesulfonyl]propiolic acid
(E3-3)

E3-3

Compound E3-2 (0.95g, 2.38 mmol) was dissolved in MeOH (15 ml) and
cooled to 0°C. A solution of Oxone® (1.77g, 5.7 mmol) in water (15 ml) was
added and the resulting mixture stirred at 0°C for 1 hour then at room temperature
overnight. The MeOH was removed *in vacuo* and the residue partitioned between
ethyl acetate and water. The aqueous phase was extracted several more times with
ethyl acetate. The combined organic extracts were washed with brine, dried over
MgSO₄ and concentrated *in vacuo* to give 800 mg (78%) of a colorless foam
corresponding to compound E3-3. Anal. calculated for $C_{18}H_{26}N_2O_8S$, C: 50.22, H:
6.09, N: 6.51. Found: , C: 50.13, H: 5.86, N: 6.45. $[\alpha]_D$ -7° (c=10). MS: (m+1)
431.

53

Preparation of Compound E3-4

E3-4

To a solution of Compound E3-3(160 mg, 0.37 mmol) and N-hydroxysuccinimide (43 mg, 0.37 mmol) in dry THF (5 ml) was added dicyclohexylcarbodiimide (76 mg, 0.37 mmol) and an additional 2 ml of THF. The mixture was stirred at room temperature for 3 hours then cooled to 0°C to help precipitate dicyclohexyl urea. In the meantime, the DiBOC CBZ silyl pentapeptide I-6(565 mg, 0.337 mmol) was dissolved in absolute ethanol (10 ml) and glacial acetic acid (95 ml), degassed and then 10% Pd/C (160 mg) was added to the mixture. The mixture was stirred under an atmosphere of H_2 (balloon pressure) for 3 hrs. The catalyst was removed by filtration and the filtrate concentrated *in vacuo* to a thick oil. THF (10 ml) and acetic acid (1 ml) were added and the solvents again removed *in vacuo* to remove all residual ethanol. The above prepared NHS active ester of compound

E3-3 was filtered directly into the flask containing the deblocked pentapeptide
through a sintered glass funnel, washing the precipitated DCU with an additional
3 ml of THF. The resulting solution was made basic to Litmus paper by dropwise
addition of triethyl amine. The mixture was stirred at room temperature for an
5   additional 3 hours, then diluted with ethyl acetate, washed with saturated sodium
bicarbonate solution, and brine, then dried over MgSO$_4$ and concentrated *in
vacuo*. Flash chromatography eluting with 7:2:1 hexane:ethyl acetate:methylene
chloride gave the desired coupling product E3-4 as a mixture of isomers. The less
polar isomer yielded 140 mg having a MS = 1950.9(m+). Mixed fractions: 224
10   mg. The more polar isomer yielded 155 mg having a MS = 1951.9 (m+1). Total
yield 519 mg, 78%.

This reaction was repeated on a 0.6 mmol scale to give 400 mg of the
desired product as a mixture of isomers. Anal. calculated for $C_{93}H_{168}N_8O_{22}SSi_6$,
C: 57.25, H: 8.68, N: 5.75; Found C: 57.55, H: 8.63, N: 5.79.
15   (The stereocenter of acid E3-3 racemized in the coupling reaction.)

Preparation of Compound E3-5

E3-5

5   A solution of compound E3-4 (390 mg, 0.2 mmol, mixture of

diastereomers) in absolute ethanol (10 ml) and glacial acetic acid (10 ml) was

degassed and then treated with 10% Pd/C (390 mg). The mixture was stirred

under an atmosphere of H₂ (balloon pressure) for 2 hrs. The catalyst was removed

by filtration through Celite and the filtrate concentrated *in vacuo* being careful to

10   leave some acetic acid present. The residue was diluted with diethyl ether (175

ml) and triethylamine was added until the mixture was basic to Litmus paper

(approximately 1 ml was required). The resulting solution was stirred at room

temperature overnight, then washed with 0.1N hydrochloric acid solution, brine,

dried over MgSO₄, and concentrated *in vacuo* to give a foam. Flash

15   chromatography on silica gel eluted with 30% ethyl acetate in hexanes gave the

desired ring closed material E3-5. The less polar isomer yielded 105 mg of a

foam having a MS: (m+) 1599.9. The more polar isomer yielded 110 mg of a

foam having a MS = 1599.8(m+). Total yield was 215 mg, 67%.

Preparation of Compound E3-6

5

E3-6

The more polar isomer of compound E3-5 (160 mg, 0.1 mmol) was

dissolved in trifluoroacetic acid (5 ml) that had been cooled to 0°C. After 30 min

10   water (0.5 ml) was added and the mixture stirred an additional 30 min at 0°C. The

mixture was concentrated *in vacuo*, the residue dissolved in THF and concentrated

in vacuo. The residue was dissolved in THF (3 ml), 1N hydrochloric acid solution

(1 ml) was added, and the mixture placed in the refrigerator overnight. The

solvent removed *in vacuo* then additional THF was added and the mixture re-

15   concentrated to azeotrope off the water. This treatment provided a white solid.

This white solid was dissolved in DMF(5 ml) and the

terphenylhydroxybenzotriazole active ester (58 mg, 0.12 mmol) was added

followed by triethylamine (60 □l, 0.4 mmol). The resulting solution was stirred at

room temperature overnight, then the solvent was removed *in vacuo*. The residue

was purified by preparative RP-HPLC (step gradient 50%-70% AcN in water over

45 min). The major peak was analyzed by HPLC (C-18 u-bondpak column, 60%

AcN, 0.1% TFA in water) and the fractions containing the material which eluted

5   at 4 min were combined and freeze dried to give 65 mg (56% yield) of E3-6 as a

white powder having a MS = 1156.6(m+).

<u>E3-7</u>

10   In analogous fashion the less polar isomer was converted to E3-7 (material

eluted in 7 min under the above described analytical conditions) to give 13 mg

(11% yield) of the desired E3-7.

FAB MS (M), calculated for $C_{58}H_{74}N_7O_{16}S$ 1156.4913; found = 1156.4924.

The following set of examples illustrate the further cleavage of the linear

15   pentapeptide to a tetrapeptide and subsequent insertion of new units onto the

linear peptide chain prior to closing.

Example 4

E4-1

To a solution of Compound I-7 (732 mg, 1.1 mmol) in anhydrous THF (25 ml) was added PyBOP® (572 mg, 1.1 mmol), N-Cbz-L-valine (304 mg, 1.21 mmol), diisopropylethyl amine (0.57 ml, 3.3 mmol), and anhydrous DMF (1.0 ml) to dissolve remaining solids. The solution was stirred at room temperature for 2 hrs. followed by removal of the solvents *in vacuo*. The residue was dissolved in anhydrous THF (40 ml), followed by addition of t-Butyldimethylsilylchloride (1.66 g, 11.0 mmol) and imidazole (750 mg, 11.0 mmol). The solution was stirred at room temperature for 18 hrs. The reaction was concentrated *in vacuo* and the residue was dissolved in Et$_2$O, washed twice with 0.1N HCl, dried over MgSO$_4$, and the solvent removed *in vacuo*. Flash chromatography (eluting with 35% EtOAc/hexane) gave 690 mg of product, 46% yield. The ^{1}H NMR (300 MHz) spectrum was consistent with the structure E4-1. FAB MS (M$^+$)= 1356.

59

E4-2

To a solution of Compound E4-1 (700 mg, 0.51 mmol) in anhydrous THF (0.6

ml) and acetonitrile (4 ml) was added N-t-Boc anhydride (0.24 ml, 1.03 mmol)

5   and dimethylaminopyridine (7 mg, 0.05 mmol). The solution was stirred for 3

hrs. Following removal of the solvents *in vacuo*, flash chromatography (eluting

with 17% EtOAc/hexane) gave 307 mg of product, 38% yield. The ^{1}H NMR (300

MHz) spectrum was consistent with the structure E4-2. FAB MS (M^+ of free

base)= 1556.

10

E4-3

To a solution of 5% Pd/C (150 mg) in EtOH (15 ml) and AcOH (15 ml) under an N₂ atmosphere was added Compound E4-2 (307 mg, 0.20 mmol). The solution was purged/filled with H₂ (x8) and subjected to constant H₂ pressure for 2.0 hrs., then filtered over Celite to remove the catalyst. The solution was concentrated *in vacuo* to remove solvents, the residue dissolved in anhydrous THF (30 ml), followed by addition of α-N-t-Boc-γ-N-Cbz-L-ornithine (80 mg, 0.22 mmol), PyBOP® (103 mg, 0.20 mmol), and diisopropylethyl amine (0.10 ml, 0.59 mmol). The reaction was stirred at room temperature for 18 hrs., followed by removal of the solvent *in vacuo*. Flash chromatography (eluting with 30% EtOAc/hexane) gave 284 mg of a white solid, 81% yield. The ¹H NMR (300 MHz) spectrum was consistent with the structure E4-3. FAB MS (M⁺ of free base)= 1771.

E4-4

To an N_2 purged solution of Compound E4-3 (279 mg, 0.16 mmol) in EtOH
(13 ml) and AcOH (12 ml) was added 5% Pd/C (150 mg). The reaction was
purged/filled with H_2 (x10) and left under constant H_2 pressure for 2 hrs.,
followed by removal of the catalyst by filtration over Celite and removal of
solvents *in vacuo*. The resulting oil was dissolved in Et_2O (75 ml) followed by
addition of triethylamine (5 ml, 35.9 mmol). After 18 hrs., the reaction was
concentrated *in vacuo*, and flash chromatography (eluting with 34%
EtOAc/hexane) gave 96 mg of product, 43% yield. The ^1H NMR (300 MHz)
spectrum was consistent with the structure E4-4. FAB MS (M^+ of free base)=
1420.

E4-5

A solution of Compound E4-4 (93 mg, 0.07 mmol) in ice cold TFA (2 ml) was placed in a 0°C freezer for 2 hrs., followed by addition of ice cold water (2 ml) and was then stirred in an ice bath for 2 hrs. The solution was concentrated *in vacuo* to yield 66 mg white solids, which were dissolved in THF (1.5 ml) and HCl (1.5 ml, 1.0N) and stirred at room temperature for 16 hrs. Toluene was added and the solution was concentrated *in vacuo* three times to assist in removal of TFA, giving 44.5 mg of an off-white solid, 91% yield. The ^{1}H NMR (300 MHz) spectrum was consistent with the structure E4-5. FAB MS (M$^+$ of free base)= 748.

E4-6

To a solution of Compound E4-5 (44 mg, 0.06 mmol) in anhydrous DMF (2

ml), was added diisopropylethyl amine (0.03 ml, 0.18 mmol) and the

5   hydroxybenzotriazole active ester of the terphenyl side chain (34 mg, 0.07 mmol).

The solution was stirred at room temperature for 40 hrs. Solvent was removed *in*

vacuo and the residue was treated with Et₂O (10 ml), sonicated, and a brown solid

was isolated by filtration. RP-HPLC (eluting with 30-70% ACN/0.1% TFA/H₂O)

and freeze drying gave 18.7 mg of a white solid, 29% yield. The ¹H NMR (300

10   MHz) spectrum was consistent with the structure E4-6. FAB MS (M⁺ of free

base)= 1090.

Example 5

Example 5 further exemplifies the insertion of new units onto a tetrapeptide

15   chain followed by ring closure to produce a new cyclic peptide Echinocandin-type

structure.

E5-1

To a solution of tetrapeptide I-7 (700 mg, 1.05 mmol) in anhydrous THF (20

ml) was added PyBOP® (547 mg, 1.05 mmol), N-Cbz-L-tyrosine (364 mg, 1.16

5   mmol), N,N-diisopropylethylamine (0.55 ml, 3.15 mmol). The solution was

stirred at room temperature for 3 hrs. followed by removal of the solvents *in*

vacuo. Used directly in the next reaction.

E5-2

10   The above residue E5-1 was dissolved in anhydrous DMF (10 ml),

followed by addition of t-Bu-dimethylsilyl chloride (1.90 g, 12.6 mmol) and

imidazole (860 mg, 12.6 mmol) and the solution was stirred at room temperature

for 18 hrs. The reaction was concentrated *in vacuo* and the residue was dissolved

in Et$_2$O, washed twice with cold 0.1N HCl, once with H$_2$O, 10% aq. sodium

bicarbonate, brine and dried over MgSO$_4$, filtered and the solvent removed *in*

5   *vacuo* to give 2.0 g crude oil. Purified by radial chromatography (eluting with

35% EtOAc/hexanes) to give 700 mg (43% yield) of product. The ^{1}H NMR (300

MHz) spectrum was consistent with the structure E5-2. FAB MS (M$^+$)= 1534.

10   **E5-3**

To a solution of Compound E5-2 (700 mg, 0.46 mmol) in anhydrous THF (10

ml) was added N-t-Boc anhydride (0.41 ml, 1.78 mmol) in portions and

dimethylaminopyridine (7 mg, 0.05 mmol), and the solution was stirred for 3 hrs.

at ambient temperature. Following removal of solvents *in vacuo*, purification by

15   radial chromatography (eluting with 20% EtOAc/hexanes) gave 460 mg of

product, 58% yield. The ^{1}H NMR (300 MHz) spectrum was consistent with the

structure

E5-3. FAB MS (M$^+$ of free base)= 1735.

E5-4

To a solution of 10% Pd/C (270 mg) in EtOH (10 ml) and AcOH (10 ml) under an N_2 atmosphere was added Compound E5-3 (460 mg, 0.27 mmol). The solution was purged/filled with H_2 (x4) and subjected to constant H_2 pressure for 2.0 hrs. at ambient temperature, then filtered over Celite to remove catalyst. The solution was concentrated *in vacuo* to remove solvents, the residue dissolved in anhydrous THF (30 ml), followed by addition of α-N-t-Boc-γ-N-Cbz-L-ornithine-N-hydroxysuccinimide ester (172 mg, 0.37 mmol), and triethylamine to pH 8($\approx$5 ml). The reaction was stirred at room temperature for 3 hrs. Diluted the reaction with ether and washed with saturated sodium bicarbonate, 0.1N HCl, saturated sodium bicarbonate, and dried over magnesium sulfate. Filtered and concentrated *in vacuo*. Radial chromatography (eluting with 30% EtOAc/hexanes) gave 280 mg of a white solid, 54% yield. The ^{1}H NMR (300 MHz) spectrum was consistent with the structure E5-4. FAB MS (M^+ of free base)= 1949.

E5-5

    To an N_2 purged solution of Compound E5-4 (280 mg, 0.14 mmol) in EtOH

(10 ml) and AcOH (5 ml) was added 10% Pd/C (200 mg). The reaction was

purged/filled with H_2 (x4) and left under constant H_2 pressure for 2 hrs., followed

by removal of the catalyst by filtration over Celite. The resulting oil was

dissolved in Et_2O (10 ml) followed by addition of triethylamine (4 ml, 28.7

mmol). After 18 hrs., the reaction was concentrated *in vacuo*, and purified by

radial chromatography (eluting with 40% EtOAc/hexanes) gave 130 mg of

product, 57% yield. The ^1H NMR (300 MHz) spectrum was consistent with the

structure E5-5. FAB MS (M^+ of free base)= 1597.

E5-6

A solution of Compound E5-5 (128 mg, 0.08 mmol) in ice cold TFA (2

ml) was placed in 0°C freezer for 2 hrs., followed by addition of ice cold water (2

ml) and was then stirred in an ice bath for 2 hrs. The solution was concentrated *in*

vacuo, then dissolved in THF (1.5 ml) and 1N HCl (1.5 ml) and stirred at room

temperature for 16 hrs. Toluene was added and the solution was concentrated *in*

vacuo three times, giving 70 mg of a dihydrochloride white solid, 100% yield.

The ^{1}H NMR (300 MHz) spectrum was consistent with the structure E5-6. FAB

MS calculated for M+H $C_{39}H_{54}N_7O_{12}$= 812.3830; found = 812.3837.

E5-7

To a solution of Compound E5-6 (65 mg, 0.08 mmol) in anhydrous DMF (5

ml), was added N,N-diisopropylethylamine (2.0 ml, 11.5 mmol) and the

5   hydroxybenzotriazole active ester of the terphenyl side chain (50 mg, 0.11 mmol),

and the solution was stirred at room temperature for 18 hrs. Solvent was removed

in vacuo and the residue was treated with Et_2O (10 ml), sonicated, and a beige

solid was isolated. The methanol soluble portion was purified by RP HPLC

(Waters Bondapak C-18, eluting with 58% AcN/0.1% TFA/H_2O at a flow of 20

10   ml/min) and freeze drying gave 35 mg of a white solid, 38% yield. The ^1H NMR

(300 MHz) spectrum was consistent with the structure E5-7. FAB MS calculated

for M+H $C_{63}H_{76}N_7O_{14}$ = 1154.5450; found = 1154.5458.

Example 6 illustrates the introduction of a water solubilizing group onto the

tetrapeptide intermediate prior to cyclization.

15

Example 6

E6-1

N-α-Boc-L-α,β- diaminopropionic acid (0.5 g, 2.45 mmol)(available from

Bachem) and 1,3-Bis(benzyloxycarbonyl)-2-methyl-2-thiopseudourea (0.88 g,

2.45 mmol) were combined in 15 ml of anhydrous DMF. Triethylamine (1.0 ml,

7.3 mmol) was added and stirred for 3 days at ambient temperature. The reaction

was diluted with 100 ml of 0.1 N NaOH and extracted into ether. The aqueous

layer was then acidified with cold saturated citric acid and extracted with ethyl

acetate (3 X 200 ml). The combined organics were dried over MgSO$_4$, filtered

and concentrated to a quantitative yield of a thick colorless oil. The ^{1}H NMR

(300 MHz) spectrum was consistent with structure E6-1. FD MS (M$^+$ of free

base)= 515.

E6-2

To the above acid E6-1 (310 mg, 0.60 mmol) in anhydrous THF (10 ml)

was added N-hydroxysuccinimide (69 mg, 0.60 mmol) and DCC (123 mg, 0.60

mmol). A white precipitate began to form after about 1 hr. The reaction was
allowed to stir overnight at ambient temperature. The reaction was filtered and
the crude solution used directly in the next coupling.

E6-3

5

To a solution of the above activated ester E6-2 (366 mg, 0.60 mmol) in
anhydrous THF (10 ml) and ether (10 ml) was added Compound E5-3(920 mg,
0.60 mmol) and triethylamine (3 ml). The solution was allowed to stir overnight
(18 hrs.) at ambient temperature. The reaction was diluted with ether and washed

10
with saturated sodium bicarbonate (1 X 250 ml), 0.1 N HCl (1 X 250 ml),
saturated sodium bicarbonate (1 X 250 ml), dried over magnesium sulfate, filtered
and concentrated to 1.0 g crude white solid. The product was purified by radial
chromatography (eluting with 30/70 ethyl acetate/hexanes) to give 550 mg (46%
yield) of a white solid. The ^{1}H NMR (300 MHz) spectrum was consistent with

15
structure E6-3. FAB MS (M$^+$ of free base)= 2036.

72

E6-4

To a solution of 5% Pd/C (150 mg) in EtOH (15 ml) and AcOH (15 ml) under
an N_2 atmosphere was added Compound E6-3 (550 mg, 0.27 mmol). The solution
was purged/filled with H_2 (x4) and subjected to constant H_2 pressure for 2.0 hrs.,
then filtered over Celite to remove the catalyst. The solution was concentrated *in
vacuo* to remove the solvents, the residue dissolved in acetonitrile (10 ml) and
ether (3 ml), followed by addition of 2 ml of triethylamine. The mixture was
sonicated for 4 hours and the temperature allowed to reach 40°C. The reaction
mixture was concentrated and purified by radial chromatography (eluting with
40/60 ethyl acetate/hexanes) to give 57 mg of the desired compound (14% yield).
The ^{1}H NMR (300 MHz) spectrum was consistent with the structure E6-4. FAB
MS (M^+ of free base)= 1549.

E6-5

To the above compound E6-4 (77 mg, 0.05 mmol) was added 3 ml of neat

trifluoroacetic acid while cooling to 0°C. After 45 minutes, 0.5 ml of water was

5   added while maintaining the reaction at 0°C. After 30 minutes, the mixture was

concentrated to a colorless oil. To this oil was added 2 ml of THF and 2 ml of 1N

HCl and refrigerated overnight. Toluene was stripped from the mixture to give a

quantitative yield of the free amine as the trihydrochloride salt. The ^{1}H NMR

(300 MHz) spectrum was consistent with the structure E6-5. FAB MS (M$^+$ of free

10   base)= 764.

E6-6

To a solution of Compound E6-5 (50 mg, 0.06 mmol) in anhydrous DMF (5

ml), was added N,N-diisopropylethylamine (2 ml) and the hydroxybenzotriazole

5   active ester of the terphenyl side chain (44 mg, 0.09 mmol), and the solution was

stirred at room temperature for 18 hrs. The solvent was removed *in vacuo* and the

residue was triturated with a mixture of acetonitrile and ether. The solid was

dried to 25 mg of a crude white solid. The product was purified by RP HPLC on

a Waters Bondapak C-18 column eluting with 55% AcN/0.1% TFA/H$_2$O at a flow

10   of 20 ml/min. The appropriate fractions were freeze dried to give 10.0 mg of a

white solid, 18% yield. The ^{1}H NMR (300 MHz) spectrum was consistent with

the structure E6-6. FAB MS calculated for (M+H) C$_{57}$H$_{72}$N$_9$O$_{14}$ = 1106.5199;

found = 1106.5185

Table 3 summarizes the activity data for compounds

15   E3-6, E4-6, E5-7 and E6-6 in comparison with the comparative semi-synthetic

Echinocandin compound C1. The same testing procedures were used as described

in Example 1 above.

Table 3

Example No.	Minimal Inhibitory Concentration (MIC) μg/ml			
	C. albicans	C. parapsilosis	A. fumigatus	Histoplasma capsulatum
Comparative C1	0.01	0.156	0.02	0.01
E3-6	10	>20	20	10
E3-7	>20	>20	>20	>20
E4-6	1.25	>20	>20	>20
E5-7	>20	>20	>20	>20
E6-6	0.078	>20	>20	>20

Example 7

Example 7 illustrates the formation of a cyclic heptapeptide from the

intermediate linear pentapeptide

(I-6).

Preparation of N-α-BOC-D-2,3-diaminopropionic acid (E7-1)

E7-1

To a 1:1 dimethylformamide:water solution (170 ml) of

[bis(trifluoroacetoxy)iodo]benzene (12.89 g, 32.29 mmol, 1.5 equiv) was added

N-α-BOC-D-asparagine (5 g, 21.53 mmol, 1 equiv). This solution stirred at room

temperature for .5 h before pyridine (3.4 g, 43.06 mmol, 2 equiv) was added.

After 18 h the reaction was concentrated *in vacuo* and the residue was redissolved

in water before being washed with diethyl ether (2X, 50 ml). The aqueous layer

was concentrated *in vacuo* and the crude product was recrystallized from hot

acetonitrile to give E7-1 (1.10 g, 25% yield).

Preparation of N-α-BOC-D-2,3-diaminopropionic acid-N-CBZ-glycine dipeptide

5   *(E7-2)*

E7-2

An aqueous solution (12 ml) of N-α-BOC-D-2,3-diaminopropionic acid

10   E7-1 (1.114 g, 5.45 mmol, 1 equiv) and NaHCO₃ (0.458 g, 5.45 mmol, 1 equiv)

was stirred rapidly for 15 minutes until complete solvation. To this was added a

1,2-dimethoxyethane solution (22 ml) of N-CBZ-O-N-hydroxysuccinimide

glycine ester. After stirring at room temperature for 18 hours the reaction was

concentrated *in vacuo*. The residue was redissolved in water, acidified to pH 3

15   with 1N aqueous HCl, and partitioned between ethyl acetate and water. The

aqueous layer was washed 3X with additional water before organics were

combined, dried over MgSO₄, and concentrated. The crude white foam was

purified on reverse phase, C-18 column, preparative HPLC (gradient 5:95

AcN/0.01%TFA to 100%AcN elution scheme) to afford 1.46 g (3.69 mmol, 68 %

20   yield) of E7-2.

Preparation of N-α-BOC-D-2,3-diaminopropionic acid-N-CBZ-glycine dipeptide-

O-NHS active ester (E7-3)

5

E7-3

10

To a 1,2-dimethoxyethane solution (40 ml) of E7-2 (1.40 g, 3.54 mmol, 1

equiv) and N-hydroxysuccinimide (0.448 g, 3.89 mmol, 1.1 equiv) cooled to 0^0C

was added dicyclohexylcarbodiimide (0.804 g, 3.89 mmol, 1.1 equiv). After

stirring for 1 h at 0^0C it was set in the refrigerator for 18 hours. The solution was

then filtered and the filtrate was stripped to dryness and placed on high vacuum

for 2 hours to give approximately 2 g of product (contained some DCU

15   byproduct) which was used without further purification.

20

5   *DiBOC silyl N(α)BOC-D-2,3-diaminopropionic acid-glycine-CBZ heptapeptide*
       (E7-4)

E7-4

10   A solution of linear peptide intermediate I-6 (1.0 g, 0.598 mmol) in

ethanol (5 ml) was added to a slurry of 10% Pd/C (250 mg) in 5 ml of ethanol

followed by 10 ml of glacial acetic acid. The mixture was put under a balloon of

H_2 and after 1 hr the starting material was gone (TLC 25% ethyl acetate/hexane).

The catalyst was removed by filtration through a Celite plug and the solution was

15   carefully reduced (but not to dryness) under high vacuum keeping the temperature

under 40^0C. The resulting oil was dissolved in 25 ml of ether and a 10 ml

79

tetrahydrofuran solution of dipeptide active ester E7-3 (O-Suc-Nα-BOC-D-2,3-

diaminopropionic acid-N-CBZ-glycine) was added followed by excess

triethylamine until the solution was basic to pH paper. After stirring for 16 hrs.,

the solution was extracted with saturated $NaHCO_3$ solution followed by dilute

5   HCl solution and then another portion of saturated $NaHCO_3$ solution. The organic

layer was dried over $MgSO_4$ and reduced *in vacuo* to give 1.194 g of the crude

product. Purification by flash chromatography (30% ethyl acetate/hexane) gave

0.674 g (59% yield) of coupled product E7-4. FAB MS = 1916.5 (M+1)

10   *Cyclization of E7-4 to BOC silyl cycloheptapeptide (E7-5)*

E7-5

An ethanol/acetic acid solution (10 ml of each) of E7-4 (0.665 g, 0.34

15   mmol) with 10% Pd/C (200 mg) was placed under a balloon of hydrogen. After

1.5 hrs., TLC (30% ethyl acetate/hexane) indicated a complete reaction. The

catalyst was removed by filtration through a plug of Celite and the solvent

reduced *in vacuo* (but not to dryness) at 40^0C until the residue was a thick oil.

This material was dissolved in ethyl ether (150 ml) and excess triethylamine (~8

ml) was added. After 18 hrs., TLC (30% ethyl acetate/hexane) indicated one

major product spot. The solvent was removed *in vacuo* and the residue was

redissolved in ethyl acetate and washed several times with water. The organics

5   were combined and dried over MgSO₄ and the solvent removed *in vacuo* to give

0.800 g of crude product. This was purified over a flash column (silica gel eluted

with 30% ethylacetate/hexanes) to provide 293 mg (54% yield) of E7-5 as a white

solid. FAB MS = 1564.9

10   *Removal of protecting groups and coupling of the side chain to give E7-6*

E7-6(a)

Compound E7-5 (288 mg, 0.181 mmol) was dissolved in trifluoroacetic

15   acid (3 ml) and cooled to 0⁰C. After 0.5 hrs., water was added (0.5 ml) and the

mixture was stirred for 0.6 hrs longer. The solvent was removed *in vacuo* and the

residue was dissolved in 1N HCl (2 ml) and tetrahydrofuran (3 ml). This solution

was stirred at room temperature for 1.5 hr after which time it was set in the

refrigerator overnight. The solvent was removed under high vacuum giving a

foam residue which was dissolved in anhydrous dimethylformamide (3 ml).

Terphenyl hydroxybenzotriazole active ester (108 mg, 0.276 mmol) and

triethylamine (0.11 ml, 0.78 mmol) were added to the solution. After stirring

overnight at room temperature the solvents were removed under high vacuum and

5   the crude material (380 mg) was purified by preparative RP-HPLC (C-18 column

eluted with a 50% AcN/0.01%TFA aqueous solution). Lyophilization of the pure

fractions gave 97 mg (48% yield) of E7-6(a) as a white solid. FAB MS = 1121.5

(M) calc. for $C_{58}H_{72}N_8O_{15}$ = 1121.21

10 . *Preparation of E7-6(b)*

In a similar manner, N-α-BOC-L-asparagine was converted to E7-6(b).

E7-6(b)

15   The H-NMR data was consistent with the structure E7-6(b). MS(FAB) =

1121 (M+)

Preparation of N-α-CBZ-D-2,3-diaminopropionic acid (E7-7)

E7-7

5   Compound E7-7 was prepared in a similar manner to N-α-BOC-diamino

propionic acid E7-1. MS FAB (M+1) = 239

Preparation of N-α-CBZ-N-β-BOC-D-2,3-diaminopropionic acid (E7-8)

E7-8

10

     To a stirring solution of sodium hydroxide (148 mg, 3.69 mmol, 1.1 equiv)

in water (5 ml) was added N-α-CBZ-diamino propionic acid E7-7. The reaction

was stirred for 10 minutes before tert-butyl alcohol (4 ml) was added. The

reaction was cooled to 0^0C and di-tert-butyl dicarbonate (807 mg, 3.69 mmol, 1.1

15   equiv) was added slowly over 0.5 h. After stirring overnight at room temperature,

the reaction was diluted with water (5 ml) and washed 3X with 10 ml ethyl ether.

The organics were then combined and washed several times with saturated

aqueous sodium bicarbonate. The aqueous layers were combined, cooled to 0^0C,

and acidified to pH 3 with aqueous potassium hydrogen sulfate (30 g in 200 ml

20   stock solution). This cloudy solution was then extracted several times with ethyl

83

acetate. The organics were combined, dried over MgSO$_4$, and concentrated *in vacuo* to give after overnight high vacuum 0.990 g (2.9 mmol, 87% yield) of E7-8. The ^{1}H NMR was consistent with structure E7-8. MS FAB (M+1) = 339

5

Preparation of N-β-BOC-D-2,3-diaminopropionic acid (E7-9)

E7-9

10

To an ethyl alcohol solution (20 ml) of N-α-CBZ-N-β-BOC-D-2,3-diaminopropionic acid E7-8 was added 10% palladium on carbon catalyst (approx. 200 mg). The mixture was placed under an H$_2$ atmosphere and stirred

15 vigorously. Due to gel like formation, the reaction required additional ethyl alcohol (total volume of 75 ml) to facilitate easy stirring. After several hours, the reaction was filtered through a plug of Celite and then concentrated *in vacuo* to give 259 mg (1.27 mmol, 32 % yield) of E7-9.

Preparation of N-β-BOC-D-2,3-diaminopropionic acid-N-CBZ-glycine dipeptide
(E7-10)

E7-10

5

Compound E7-10 was prepared in a similar manner as N-α-BOC-D-2,3-
diaminopropionic acid-N-CBZ-glycine dipeptide E7-2.
The ^{1}H NMR was consistent with the structure E7-10.

10   *Preparation of N-β-BOC-D-2,3-diaminopropionic acid-N-CBZ-glycine dipeptide-*
*O-NHS active ester (E7-11)*

E7-11

15   Compound E7-11 was prepared in a similar manner as N-α-BOC-D-2,3-
diaminopropionic acid-N-CBZ-glycine dipeptide-O-NHS active ester E7-3.

Preparation of DiBOC silyl N(β)BOC-D-2,3-diaminopropionic acid-glycine-CBZ

heptapeptide (E7-12)

E7-12

5   Compound E7-12 was prepared in a similar manner as DiBOC silyl

N(α)BOC-D-2,3-diaminopropionic acid-glycine-CBZ heptapeptide E7-4. MS

FAB (M+1) = 1917

*Preparation of BOC silyl cycloheptapeptide (E7-13)*

E7-13

10

Compound E7-13 was prepared in a similar manner as BOC silyl

cycloheptapeptide E7-5.

Preparation of Cycloheptapeptide E7-14(a)

5

E7-14(a)

Compound E7-14 was prepared in a similar manner as cycloheptapeptide

E7-6. MS FAB (M) = 1121.6

10

Preparation of Cycloheptapeptide E7-14(b)

In a similar manner as E7-14(a), E7-14(b) was prepared from N-α-CBZ-L-2,3-diamino propionic acid.

5

E7-14(b)

The H¹-NMR data was consistent with structure E7-14(b). MS(FAB) = 1121 (M+)

10   **Example 8**

Preparation of (-L-)-(α)-N-CBZ-(β)-N-trifluoroacetyl 2,3-diaminopropionic acid (E8-1)

15   **E8-1**

The procedure of Curphey et al., *J. Org. Chem.*, **44**, 2805, (1979) was utilized

as follows. A suspension of (-L)-(α)-N-CBZ-2,3-diaminopropionic acid (2.0 g,

8.39 mmol) and triethylamine (0.84 g, 8.39 mmol) in methanol (10 ml) at ambient

temperature was treated with ethyl trifluoroacetate (1.49 g, 10.49 mmol) and the

5   mixture stirred for 48 hrs. The resulting solution was diluted with methanol (5

ml), cooled to 0°C, and treated with Dowex 50W resin(3.30 g). After stirring for

10 min., the suspension was filtered and the filtrate concentrated *in vacuo* to

produce 2.74 g of a white solid (98% yield) that was used without further

purification. H^1 NMR data was consistent with the structure E8-1. MS(FD) =

10   334 (M+)

Preparation of the N-hydroxysuccinimide ester (E8-2) from E8-1


15   **E8-2**

To a solution of E8-1 (1.20 g, 3.59 mmol) and N-hydroxysuccinimide

(0.45 g, 3.95 mmol) in 1,2-dimethoxyethane (20 ml) at 0°C was added N,N'-

dicyclohexylcarbodiimide (0.81 g, 3.95 mmol). The mixture was stirred at cold

bath temperature for 2 hr followed by overnight storage in the refrigerator.

20   Filtration of the suspension and subsequent concentration of the filtrate gave a

crude solid product which was recrystallized from ethyl acetate/hexanes to

produce 0.78 g of a crystalline solid (50% yield, one crop). The H^1 NMR data

was consistent with structure E8-2. MS(FD) = 431 (M+)

Preparation of dipeptide (E8-3) from amino acid active ester E8-2

E8-3

    (-L-)-(α)-N-BOC-2,3-diaminopropionic acid (0.52 g, 2.55 mmol) was dissolved in aqueous sodium bicarbonate solution (prepared from dissolving 0.22 g, 2.55 mmol of sodium bicarbonate in 10 ml of water). This solution was added to a solution of active ester E8-2 (1.1 g, 2.55 mmol) in 1,2-dimethoxyethane (23 ml) and the mixture stirred for 24 hrs. After concentration *in vacuo* to remove 1,2-dimethoxyethane, the residual suspension was adjusted to pH 5 with 1N aqueous citric acid, then extracted with ethyl acetate (2x). The combined organic extracts were washed successively with water and brine, dried over MgSO$_4$ and reduced *in vacuo* to give 1.4 g of a crude foam. Trituration with methylene chloride gave 1.05 g of a flocculent solid (75% yield). Additional product in mother liquor was not recovered.

H^1 NMR data was consistent with structure E8-3. MS(negative ion electrospray) = 519 (M-H)

Preparation of dipeptide active ester (E8-4) from dipeptide E8-3

E8-4

To a solution of E8-3 (0.65 g, 1.24 mmol) and N-hydroxysuccinimide (0.16 g, 1.37 mmol) in tetrahydrofuran (5 ml) at 0°C was added N,N'-dicyclohexylcarbodiimide (0.28 g, 1.37 mmol). The mixture was stirred at cold bath temperature for 2 hrs followed by overnight storage in the refrigerator. Filtration of the suspension and subsequent concentration of the filtrate gave 0.70 g of a crude foam (89% yield). H^1 NMR data was consistent with structure E8-4. MS(FD) = 631 (M+)

Preparation of DiBOC silyl (-L-)-(α)-N-BOC-2,3-diaminopropionic acid-(-L-)-

(α)-N-CBZ-(β)-N-trifluoroacetyl 2,3-diaminopropionic acid linear heptapeptide

(E8-5)

**E8-5**

A solution of linear pentapeptide intermediate I-6

(2.0 g, 1.19 mmol) in ethyl acetate(10 ml) was added to a slurry of 10% Pd/C (400

mg) in ethyl acetate (15 ml) followed by 20 ml of glacial acetic acid. The mixture

was put under a balloon of H_2 and after 1 hr the starting material was gone. The

catalyst was removed by filtration and the solution was carefully reduced under

high vacuum keeping the temperature under 40°C. The resulting oil was dissolved

in THF (15 ml) and the dipeptide active ester, N-(-L-)-(α)-CBZ-N-(β)-

trifluoroacetyl 2,3-diaminopropionic acid- N-(L)-(α)-BOC 2,3-diaminopropionic

acid-Osu E8-4, was added followed by excess triethylamine until the solution was

basic to pH paper. After stirring for 18 hrs., the solution was reduced *in vacuo* and

the residue partitioned between ethyl ether and water. The ether layer was washed

with saturated NaHCO₃ solution, followed by successive washings with water, 1N

aqueous citric acid, water, saturated NaHCO₃ and brine. The organic layer was

5   dried over MgSO₄ and reduced *in vacuo* to give 2.36 g of the crude product.

Purification by silica flash chromatography (25% ethyl acetate/hexane) gave 1.22

g of coupled product E8-5 as a foam (56% yield). H¹ NMR data was consistent

with structure E8-5. MS(FAB) = 2041.5 (M+)

10   *Cyclization of E8-5 to BOC silyl cycloheptapeptide (E8-6)*

E8-6

An ethyl acetate/acetic acid solution (20 ml each) of E8-5 (1.20 g, 0.58

15   mmol) with 10% Pd/C (290 mg) was placed under a balloon of hydrogen. After

1.5 hrs., TLC indicated deprotection was complete. The catalyst was removed by

filtration and the filtrate concentrated *in vacuo* to a thick slurry. This material was

dissolved in ethyl ether(120 ml) and excess triethylamine was added until the

solution was basic to pH paper(~5 ml). After 36 hrs., TLC indicated one major

product. The solution was washed successively with water, 1N aqueous citric

acid, water, and brine. The organic layer was dried over MgSO₄ and reduced *in*

5   *vacuo* to give 1.14 g of crude product. Purification by silica flash chromatography

(25% ethyl acetate/hexane) gave 0.69 g of

E8-6 as a foam (70% yield). H^1 NMR data was consistent with structure E8-6.

MS(FAB) = 1690.0(M+H)

10   *Removal of protecting groups and coupling of the side chain to generate E8-7*

E8-7

A solution of E8-6 (0.69 g, 0.40 mmol) in trifluoroacetic acid (23 ml) at

0°C was stirred for 0.5 hr after which time water (2 ml) was added and the stirring

15   continued for an additional 0.75 hr at 0°C. The solvent was removed *in vacuo* and

the residue was dissolved in tetrahydrofuran (9 ml) and treated with 1N HCl (4

ml). This solution was stirred at ambient temperature for 1.25 hr and then

refrigerated for 18 hr. HPLC showed one major product peak. Concentration *in*

vacuo produced a residual foam which after dissolution in dimethylformamide (12

ml) was treated with the terphenyl hydroxybenzotriazole active ester

(0.25 g, 0.52 mmol) and triethylamine (0.28 ml, 2.0 mmol). After stirring at

ambient temperature for 17 hrs., the solvent was removed under high vacuum and

5   the crude residue purified by preparative RP-HPLC (linear gradient 60%-100%

AcN/0.1%TFA elution scheme) to produce 0.37 g of a white solid (75% yield).

H^1 NMR data was consistent with structure E8-7. MS(FAB) = 1246.7(M+)

Final deprotection of E8-7 to generate E8-8

10

E8-8

To a solution of E8-7 (250 mg, 0.20 mmol) in methanol (12 ml) was added

a solution of potassium carbonate (138 mg, 1.0 mmol) in water (6 ml), and the

15   resulting mixture stirred at ambient temperature for 20 hrs. Solvent removal *in*

vacuo followed by purification via preparative RP-HPLC (linear gradient 60-

100% AcN/0.1%TFA elution scheme) gave 218 mg of a white solid (94% yield).

H^1 NMR data was consistent with structure E8-8. MS(FAB) = 1150.6(M+)

Reductive alkylation of E8-8 to generate E8-9

E8-9

To a solution of E8-8 (40 mg, 0.0347 mmol) in methanol (2 ml) at ambient temperature was added 1-methyl-4-piperidone (7.85 mg, 0.0694 mmol) and glacial acetic acid

(2 μl, 0.0347 mmol). The solution was treated with sodium cyanoborohydride (3.27 mg, 0.0520 mmol) and the mixture stirred for 16 hrs. After concentration *in vacuo*, the crude product was purified via preparative RP-HPLC (step gradient 40-100% AcN/0.1%TFA elution scheme) to yield 19 mg of a white solid (45% yield). H^1 NMR data was consistent with structure E8-9. MS(FAB) = 1247.6 (M+)

Table 4 summarizes the activity data for compounds
E7-6(a), E7-6(b), E7-14(a), E7-14(b), E8-8 and E8-9 in comparison with the
comparative semi-synthetic Echinocandin compound C1 and Amphotericin B.
The same testing procedures were used as described in Example 1 above.

5

Table 4

Example No.	Minimal Inhibitory Concentration (MIC) μg/ml				
	Candida albicans	Candida parapsilosis	Aspergillus fumigatus	Cryptococcus neoformans	Histoplasma capsulatum
Comparative C1	0.01	0.156	0.02	>20	0.01
Ampho B	0.078	0.038	0.312	0.039	0.039
E7-6(a) (22 membered ring)	>20	>20	>20	>20	>20
E7-6(b) (22 membered ring)	0.312	>20	5.0	>20	1.25
E7-14(a) (21 membered ring)	0.312	>20	>20	>20	0.312
E7-14(b) (21 membered ring)	0.156	>20	>20	>20	0.078
E8-8 (22 membered ring)	0.078	0.625	5.0	>20	0.312
E8-9 (22 membered ring)	0.156	5.0	5.0	>20	0.625

97

WE CLAIM:

1. A process for modifying a cyclic peptide ring nucleus comprising the steps of:

    (i)   providing a cyclic peptide compound comprising a peptide unit

5   having a γ-hydroxyl group;

    (ii) opening the ring of said cyclic peptide compound to provide a first

           linear peptide wherein said peptide unit having a γ-hydroxyl group is

           the N-terminus peptide unit of said first linear peptide;

    (iii) cleaving-off said peptide unit having a γ-hydroxyl group to

10   provide a second linear peptide;

    (iv) attaching at least one amino acid, dipeptide unit or synthetic unit to

           said second linear peptide to produce a third linear peptide;

    (v) cyclizing said third linear peptide to produce a modified cyclic

           peptide compound having a modified ring nucleus.

15

2. The process of Claim 1 wherein said amino acid, said dipeptide unit or said synthetic unit of step (iv) comprises a protected amino group.

3. The process of Claim 2 further comprising

20   (vi) deprotecting said protected amino group to provide a deprotected

           amino group;

    (vii) acylating said deprotected amino group.

4. The process of Claim 1 or Claim 2 further comprising cleaving another

25 peptide unit from said second linear peptide in step (iii) before attaching said at least one amino acid, dipeptide unit or synthetic unit in step (iv).

5. The process of Claim 1 wherein step (iii) is performed by adding trifluoroacetic acid or hydrochloric acid to said first linear peptide in an organic solvent.

5

6. The process of Claim 5 wherein said organic solvent is selected from the group consisting of methylene chloride, toluene and dioxane.

7. The process of Claim 1 or 2 wherein a second amino acid, dipeptide or

10   synthetic unit is attached to said third linear peptide in step (iv) prior to cyclizing in step (v).

8. The process of Claim 4 wherein a second amino acid, dipeptide or synthetic unit is attached to said third linear peptide in step (iv) prior to cyclizing

15   in step (v).

9. The process of Claim 1 wherein said cyclic peptide compound is a cyclic hexapeptide.

20   10. The process of Claim 1 wherein said cyclic peptide compound is represented by the following structure:

99

wherein R is an alkyl group, an alkenyl group, an alkynyl group, an aryl group, or

heteroaryl group; R^1 is -H or -OH; R^2 is -H or -CH$_3$; R^3 is -H, -CH$_3$, -CH$_2$CONH$_2$

or -CH$_2$CH$_2$NH$_2$;

5   R^4 is -H or -OH; R^5 is -OH, -OPO$_3$H$_2$, or -OSO$_3$H; and R^6 is -H or -OSO$_3$H.

11. The process of Claim 1 wherein said modified cyclic peptide compound is

a 19-, 20-, 21-, or 22-membered ring compound.

10   12. A compound prepared by the process according to Claim 10 and

represented by formula I or II:

I

5   **II**

wherein

R is an alkyl group, an alkenyl group, an alkynyl group, an aryl group, or

heteroaryl group;

R^2 is -H or -CH$_3$;

10   R^3 is -H, -CH$_3$, -CH$_2$CONH$_2$ or -CH$_2$CH$_2$NH$_2$;

R^4 is -H or -OH;

R^5 is -OH, -OPO$_3$H$_2$, or -OSO$_3$H;

R^6 is -H or -OSO$_3$H;

R^7 is -CH$_3$ or -H;

(Y) is represented by the following formula

5

$$-A-\underset{\underset{O}{\overset{\overset{\text{NH-W}}{|}}{C}}-\underset{\overset{\|}{O}}{C}-NH-\underset{\overset{|}{B}}{CH}-\underset{\overset{\|}{O}}{C}-$$

wherein

A is -(CH$_2$)$_a$- where a = 1-4, -CHR'-CHR''-(CH$_2$)$_b$- where R' and R''

are independently -H, -OH, C$_6$H$_5$O-, -SH,

-NH$_2$, C$_n$H$_{n+2}$NH-, C$_n$H$_{n+2}$O-, C$_n$H$_{n+2}$S- or -C$_n$H$_{n+2}$ where n = 1-4

and b = 0-1, -(CH$_2$)$_c$-C(O)NH(CH$_2$)$_d$- where

c = 1-2 and d = 1-2, -N=CH-(CH$_2$)$_e$- where e = 0-2, -NR'''(CH$_2$)$_f$-

where R''' is -H, -C(O)CH$_2$NH$_2$,

-C(O)CH(NH$_2$)CH$_2$NH$_2$ or -C$_n$H$_{n+2}$ where n = 1-4 and

f = 1-3, -(CH$_2$)$_g$-SO$_2$-(CH$_2$)$_h$- where g = 1-2 and

h = 1-2,

$$\underset{\underset{H}{\overset{\overset{\text{NH}}{\|}}{N}}}{CH_3-C}-(CH_2)_i-$$

where i = 1 or 2, or

20

$$\underset{\overset{\|}{O}}{\overset{\overset{\text{CH}_2\text{Z}}{|}}{CH}-C}-NH-(CH_2)_j-$$

102

where j is 1 or 2 and Z is an amino group, alkylamino group, or

piperidyl amino group; and

B is a substituted or unsubstituted C1 to C6 alkyl group;

W is a hydrogen or C(O)R where R is as defined above;

5   and pharmaceutically acceptable salts, esters or hydrates thereof.

13. A compound represented by formula I or II:

10   **I**

II

wherein

R is an alkyl group, an alkenyl group, an alkynyl group, an aryl group, or

heteroaryl group;

R^2 is -H or -CH$_3$;

R^3 is -H, -CH$_3$, -CH$_2$CONH$_2$ or -CH$_2$CH$_2$NH$_2$;

R^4 is -H or -OH;

R^5 is -OH, -OPO$_3$H$_2$, or -OSO$_3$H;

R^6 is -H or -OSO$_3$H;

R^7 is -CH$_3$ or -H;

(Y) is represented by the following formula

wherein

104

A is -$(CH_2)_a$- where a = 1, 2 or 4, -CHR'-CHR''-$(CH_2)_b$- where R' and

R'' are independently -H, -OH, C_6H_5O-, -SH, -NH_2, $C_nH_{n+2}NH$-,

$C_nH_{n+2}O$-, $C_nH_{n+2}S$- or -C_nH_{n+2} where n = 1-4 and b = 0, -$(CH_2)_c$-

$C(O)NH(CH_2)_d$- where c = 1-2 and d = 1-2, -N=CH-$(CH_2)_e$- where

e = 0-2, -$NR'''(CH_2)_f$- where R''' is -H, -$C(O)CH_2NH_2$,

-$C(O)CH(NH_2)CH_2NH_2$ or -C_nH_{n+2} where n = 1-4 and

f = 1-3, -$(CH_2)_g$-SO_2-$(CH_2)_h$- where g = 1-2 and

h = 1-2,

where i = 1 or 2, or

where j is 1 or 2 and Z is an amino group, alkylamino group, or

piperidyl amino group; and

B is a substituted or unsubstituted C1 to C6 alkyl group;

W is a hydrogen or C(O)R where R is as defined above;

and pharmaceutically acceptable salts, esters or hydrates thereof.

14. The compound of Claim 12 or 13 wherein R is a terphenyl group

represented by the structure

15. A pharmaceutical composition comprising a compound of Claim 13 and a pharmaceutically inert carrier.

5   16. The pharmaceutical composition of Claim 15 further comprising a wetting agent, lubricating agent, emulsifier, suspending agent, preservative, sweetener, stabilizer, perfuming agent, flavoring agent or combinations thereof.

17. A method of inhibiting fungal activity comprising contacting a compound

10   of Claim 13 with a fungus.

18. A method of treating a fungal infection in a human comprising administering to a human in need of such treatment a therapeutically effective amount of a compound according to Claim 13.

15

19. The method of Claim 18 wherein said compound is administered to said human topically, orally, by injection, by inhalation, or combinations thereof.

20. A method of inhibiting parasitic activity comprising contacting a

20   compound of Claim 13 with a parasite.